ID   TAU_HUMAN               Reviewed;         758 AA.
AC   P10636; P18518; Q14799; Q15549; Q15550; Q15551; Q1RMF6; Q53YB1; Q5CZI7;
AC   Q5XWF0; Q6QT54; Q9UDJ3; Q9UMH0; Q9UQ96;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   31-MAY-2011, sequence version 5.
DT   09-APR-2025, entry version 291.
DE   RecName: Full=Microtubule-associated protein tau {ECO:0000305};
DE   AltName: Full=Neurofibrillary tangle protein;
DE   AltName: Full=Paired helical filament-tau;
DE            Short=PHF-tau;
GN   Name=MAPT {ECO:0000312|HGNC:HGNC:6893}; Synonyms=MAPTL, MTBT1, TAU;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM FETAL-TAU).
RC   TISSUE=Brain;
RX   PubMed=3131773; DOI=10.1073/pnas.85.11.4051;
RA   Goedert M., Wischik C., Crowther R., Walker J., Klug A.;
RT   "Cloning and sequencing of the cDNA encoding a core protein of the paired
RT   helical filament of Alzheimer disease: identification as the microtubule-
RT   associated protein tau.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4051-4055(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TAU-D).
RC   TISSUE=Brain;
RX   PubMed=2498079; DOI=10.1002/j.1460-2075.1989.tb03390.x;
RA   Goedert M., Spillantini M.G., Potier M.-C., Ulrich J., Crowther R.A.;
RT   "Cloning and sequencing of the cDNA encoding an isoform of microtubule-
RT   associated protein tau containing four tandem repeats: differential
RT   expression of tau protein mRNAs in human brain.";
RL   EMBO J. 8:393-399(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TAU-A AND FETAL-TAU).
RC   TISSUE=Fetal brain;
RX   PubMed=2516729; DOI=10.1016/0896-6273(89)90050-0;
RA   Lee G., Neve R.L., Kosik K.S.;
RT   "The microtubule binding domain of tau protein.";
RL   Neuron 2:1615-1624(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TAU-B; TAU-C; TAU-E AND TAU-F), AND
RP   ASSOCIATION WITH ALZHEIMER DISEASE.
RC   TISSUE=Brain;
RX   PubMed=2484340; DOI=10.1016/0896-6273(89)90210-9;
RA   Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A.;
RT   "Multiple isoforms of human microtubule-associated protein tau: sequences
RT   and localization in neurofibrillary tangles of Alzheimer's disease.";
RL   Neuron 3:519-526(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS PNS-TAU; FETAL-TAU AND TAU-F),
RP   ALTERNATIVE SPLICING, AND VARIANT HIS-441.
RX   PubMed=1420178; DOI=10.1021/bi00158a027;
RA   Andreadis A., Brown W.M., Kosik K.S.;
RT   "Structure and novel exons of the human tau gene.";
RL   Biochemistry 31:10626-10633(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TAU-E).
RA   Chun J., Kwon T., Lee E.-J., Hyun S.-H., Kang S.S.;
RT   "Cloning of tau-related genes.";
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM FETAL-TAU).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS FETAL-TAU AND TAU-D).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-73; 103-381; 468-497; 508-571; 577-583; 592-607;
RP   616-634; 639-657; 661-664; 671-700 AND 703-758, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND DEAMIDATION AT ASN-484 AND ASN-596.
RC   TISSUE=Brain;
RX   PubMed=1512244; DOI=10.1016/s0021-9258(18)41890-x;
RA   Hasegawa M., Morishima-Kawashima M., Takio K., Suzuki M., Titani K.,
RA   Ihara Y.;
RT   "Protein sequence and mass spectrometric analyses of tau in the Alzheimer's
RT   disease brain.";
RL   J. Biol. Chem. 267:17047-17054(1992).
RN   [11]
RP   PROTEIN SEQUENCE OF 25-44; 529-538; 560-571 AND 671-686, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RC   TISSUE=Fetal brain cortex;
RA   Lubec G., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 466-740 (ISOFORMS
RP   TAU-A/TAU-B/TAU-C/FETAL-TAU).
RA   Han J., Zhang J., Dong X.-P.;
RT   "Molecular interactions of recombinant neural protein tau with recombinant
RT   and native PrP proteins in vitro.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   PROTEIN SEQUENCE OF 543-551; 560-574; 576-584 AND 623-634, PHOSPHORYLATION
RP   AT SER-531; THR-534; THR-548; SER-552; SER-554; SER-579; SER-713 AND
RP   SER-739, UBIQUITINATION AT LYS-571; LYS-628 AND LYS-670, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY.
RX   PubMed=16443603; DOI=10.1074/jbc.m512786200;
RA   Cripps D., Thomas S.N., Jeng Y., Yang F., Davies P., Yang A.J.;
RT   "Alzheimer disease-specific conformation of hyperphosphorylated paired
RT   helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6
RT   ubiquitin conjugation.";
RL   J. Biol. Chem. 281:10825-10838(2006).
RN   [14]
RP   PROTEIN SEQUENCE OF 577-584; 608-611; 616-628; 639-648 AND 671-686,
RP   PHOSPHORYLATION AT SER-579; SER-610; SER-622; SER-641 AND SER-673,
RP   MUTAGENESIS, AND DOMAIN.
RX   PubMed=7706316; DOI=10.1074/jbc.270.13.7679;
RA   Drewes G., Trinczek B., Illenberger S., Biernat J., Schmitt-Ulms G.,
RA   Meyer H.E., Mandelkow E.-M., Mandelkow E.;
RT   "Microtubule-associated protein/microtubule affinity-regulating kinase
RT   (p110mark). A novel protein kinase that regulates tau-microtubule
RT   interactions and dynamic instability by phosphorylation at the Alzheimer-
RT   specific site serine 262.";
RL   J. Biol. Chem. 270:7679-7688(1995).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 592-622 (ISOFORMS PNS-TAU/TAU-D/TAU-E/TAU-F).
RC   TISSUE=Brain;
RX   PubMed=2495000; DOI=10.1016/0006-291x(89)92240-7;
RA   Mori H., Hamada Y., Kawaguchi M., Honda T., Kondo J., Ihara Y.;
RT   "A distinct form of tau is selectively incorporated into Alzheimer's paired
RT   helical filaments.";
RL   Biochem. Biophys. Res. Commun. 159:1221-1226(1989).
RN   [16]
RP   PROTEIN SEQUENCE OF 251-264 AND 379-392, AND PHOSPHORYLATION AT SER-396.
RX   PubMed=1899488; DOI=10.1126/science.1899488;
RA   Lee V.M., Balin B.J., Otvos L. Jr., Trojanowski J.Q.;
RT   "A68: a major subunit of paired helical filaments and derivatized forms of
RT   normal Tau.";
RL   Science 251:675-678(1991).
RN   [17]
RP   PROTEIN SEQUENCE OF 616-712.
RX   PubMed=1915258; DOI=10.1002/j.1460-2075.1991.tb07820.x;
RA   Jakes R., Novak M., Davison M., Wischik C.M.;
RT   "Identification of 3- and 4-repeat tau isoforms within the PHF in
RT   Alzheimer's disease.";
RL   EMBO J. 10:2725-2729(1991).
RN   [18]
RP   IDENTIFICATION (ISOFORM TAU-G), AND VARIANT HIS-441.
RX   PubMed=15365985; DOI=10.1002/humu.20086;
RA   Rademakers R., Cruts M., van Broeckhoven C.;
RT   "The role of tau (MAPT) in frontotemporal dementia and related
RT   tauopathies.";
RL   Hum. Mutat. 24:277-295(2004).
RN   [19]
RP   REVIEW.
RX   PubMed=1713721; DOI=10.1016/0166-2236(91)90105-4;
RA   Goedert M., Crowther R.A., Garner C.C.;
RT   "Molecular characterization of microtubule-associated proteins tau and
RT   MAP2.";
RL   Trends Neurosci. 14:193-199(1991).
RN   [20]
RP   PHOSPHORYLATION AT SER-554; SER-579; SER-602; SER-622 AND SER-669.
RX   PubMed=8999860; DOI=10.1016/s0021-9258(19)67481-8;
RA   Paudel H.K.;
RT   "The regulatory Ser262 of microtubule-associated protein tau is
RT   phosphorylated by phosphorylase kinase.";
RL   J. Biol. Chem. 272:1777-1785(1997).
RN   [21]
RP   GLYCATION AT LYS-87; LYS-383; LYS-467; LYS-480; LYS-491; LYS-542; LYS-551;
RP   LYS-576; LYS-597; LYS-598; LYS-664; LYS-670 AND LYS-686, AND LACK OF
RP   GLYCATION AT LYS-24; LYS-44; LYS-67; LYS-381; LYS-391; LYS-392; LYS-394;
RP   LYS-465; LYS-497; LYS-507; LYS-541; LYS-557; LYS-571; LYS-574; LYS-584;
RP   LYS-591; LYS-607; LYS-611; LYS-615; LYS-628; LYS-634; LYS-638; LYS-648;
RP   LYS-657; LYS-660; LYS-687; LYS-692; LYS-700; LYS-702; LYS-712 AND LYS-755.
RX   PubMed=9326300; DOI=10.1046/j.1471-4159.1997.69041709.x;
RA   Nacharaju P., Ko L., Yen S.H.;
RT   "Characterization of in vitro glycation sites of tau.";
RL   J. Neurochem. 69:1709-1719(1997).
RN   [22]
RP   PHOSPHORYLATION, AND MUTAGENESIS.
RX   PubMed=9735171; DOI=10.1006/abbi.1998.0813;
RA   Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K.;
RT   "Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal
RT   inhibition of its binding to microtubules.";
RL   Arch. Biochem. Biophys. 357:299-309(1998).
RN   [23]
RP   PHOSPHORYLATION AT THR-470; SER-516; SER-519; THR-529; SER-531; SER-552;
RP   SER-579; SER-713; SER-721 AND SER-739, AND MUTAGENESIS.
RX   PubMed=9614189; DOI=10.1091/mbc.9.6.1495;
RA   Illenberger S., Zheng-Fischhofer Q., Preuss U., Stamer K., Baumann K.,
RA   Trinczek B., Biernat J., Godemann R., Mandelkow E.-M., Mandelkow E.;
RT   "The endogenous and cell cycle-dependent phosphorylation of tau protein in
RT   living cells: implications for Alzheimer's disease.";
RL   Mol. Biol. Cell 9:1495-1512(1998).
RN   [24]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=10747907; DOI=10.1074/jbc.m000389200;
RA   Maas T., Eidenmueller J., Brandt R.;
RT   "Interaction of tau with the neural membrane cortex is regulated by
RT   phosphorylation at sites that are modified in paired helical filaments.";
RL   J. Biol. Chem. 275:15733-15740(2000).
RN   [25]
RP   PHOSPHORYLATION AT SER-519; THR-522; SER-713 AND SER-721 BY CSNK1D/CK1, AND
RP   INTERACTION WITH CSNK1D.
RX   PubMed=14761950; DOI=10.1074/jbc.m314116200;
RA   Li G., Yin H., Kuret J.;
RT   "Casein kinase 1 delta phosphorylates tau and disrupts its binding to
RT   microtubules.";
RL   J. Biol. Chem. 279:15938-15945(2004).
RN   [26]
RP   PHOSPHORYLATION AT THR-548 BY GSK3B.
RX   PubMed=14690523; DOI=10.1111/j.1471-4159.2004.02155.x;
RA   Cho J.H., Johnson G.V.;
RT   "Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta
RT   (GSK3beta) plays a critical role in regulating tau's ability to bind and
RT   stabilize microtubules.";
RL   J. Neurochem. 88:349-358(2004).
RN   [27]
RP   PHOSPHORYLATION AT TYR-18 BY FYN.
RX   PubMed=14999081; DOI=10.1523/jneurosci.4162-03.2004;
RA   Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M.,
RA   Do L.H., Andreadis A., Van Hoesen G., Ksiezak-Reding H.;
RT   "Phosphorylation of tau by fyn: implications for Alzheimer's disease.";
RL   J. Neurosci. 24:2304-2312(2004).
RN   [28]
RP   INTERACTION WITH SQSTM1, UBIQUITINATION, AND PROTEASOMAL DEGRADATION.
RX   PubMed=15953362; DOI=10.1111/j.1471-4159.2005.03181.x;
RA   Babu J.R., Geetha T., Wooten M.W.;
RT   "Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal
RT   degradation.";
RL   J. Neurochem. 94:192-203(2005).
RN   [29]
RP   PHOSPHORYLATION AT THR-498; SER-516; SER-519; THR-522; THR-529; SER-531;
RP   THR-548; SER-552; SER-579; SER-713; SER-721 AND SER-726, AND
RP   DEPHOSPHORYLATION AT THR-498; SER-516; SER-519; THR-522; THR-529; SER-531;
RP   THR-548; SER-552; SER-579; SER-713; SER-721 AND SER-726 BY PPP5C.
RX   PubMed=15546861; DOI=10.1074/jbc.m410775200;
RA   Liu F., Iqbal K., Grundke-Iqbal I., Rossie S., Gong C.X.;
RT   "Dephosphorylation of tau by protein phosphatase 5: impairment in
RT   Alzheimer's disease.";
RL   J. Biol. Chem. 280:1790-1796(2005).
RN   [30]
RP   PHOSPHORYLATION AT TYR-514; SER-515; SER-516; SER-519; SER-733; SER-739 AND
RP   THR-744.
RX   PubMed=16923168; DOI=10.1111/j.1471-4159.2006.04059.x;
RA   Sato S., Cerny R.L., Buescher J.L., Ikezu T.;
RT   "Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is
RT   involved in tau phosphorylation and aggregation.";
RL   J. Neurochem. 98:1573-1584(2006).
RN   [31]
RP   PHOSPHORYLATION AT SER-214 BY SGK1, AND INTERACTION WITH SGK1.
RX   PubMed=16982696; DOI=10.1128/mcb.01017-06;
RA   Yang Y.C., Lin C.H., Lee E.H.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) increases neurite
RT   formation through microtubule depolymerization by SGK1 and by SGK1
RT   phosphorylation of tau.";
RL   Mol. Cell. Biol. 26:8357-8370(2006).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [33]
RP   PHOSPHORYLATION BY CSNK1D/CK1.
RX   PubMed=17562708; DOI=10.1074/jbc.m703269200;
RA   Hanger D.P., Byers H.L., Wray S., Leung K.-Y., Saxton M.J., Seereeram A.,
RA   Reynolds C.H., Ward M.A., Anderton B.H.;
RT   "Novel phosphorylation sites in tau from Alzheimer brain support a role for
RT   casein kinase 1 in disease pathogenesis.";
RL   J. Biol. Chem. 282:23645-23654(2007).
RN   [34]
RP   PHOSPHORYLATION AT THR-529 BY DYRK2.
RX   PubMed=18599021; DOI=10.1016/j.bcp.2008.05.021;
RA   Yoshida K.;
RT   "Role for DYRK family kinases on regulation of apoptosis.";
RL   Biochem. Pharmacol. 76:1389-1394(2008).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-519, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [37]
RP   GLYCOSYLATION, PHOSPHORYLATION AT SER-516; SER-519; THR-522; THR-529;
RP   SER-531; THR-534; SER-579; SER-713; SER-721 AND SER-739, AND ASSOCIATION
RP   WITH ALZHEIMER DISEASE.
RX   PubMed=19451179; DOI=10.1093/brain/awp099;
RA   Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K.,
RA   Gong C.X.;
RT   "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau
RT   pathology in Alzheimer's disease.";
RL   Brain 132:1820-1832(2009).
RN   [38]
RP   INTERACTION WITH EPM2A.
RX   PubMed=19542233; DOI=10.1074/jbc.m109.009688;
RA   Puri R., Suzuki T., Yamakawa K., Ganesh S.;
RT   "Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an
RT   animal model for Lafora disease.";
RL   J. Biol. Chem. 284:22657-22663(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-713; SER-717; SER-721 AND
RP   SER-726, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [41]
RP   GLYCOSYLATION AT SER-525; SER-555 AND SER-717, PHOSPHORYLATION AT SER-519;
RP   SER-713 SER-717 AND SER-721, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=21327254; DOI=10.1039/c0mb00337a;
RA   Smet-Nocca C., Broncel M., Wieruszeski J.M., Tokarski C., Hanoulle X.,
RA   Leroy A., Landrieu I., Rolando C., Lippens G., Hackenberger C.P.;
RT   "Identification of O-GlcNAc sites within peptides of the Tau protein and
RT   their impact on phosphorylation.";
RL   Mol. Biosyst. 7:1420-1429(2011).
RN   [42]
RP   FUNCTION, AND PHOSPHORYLATION AT THR-529 AND SER-579.
RX   PubMed=21985311; DOI=10.1111/j.1471-4159.2011.07523.x;
RA   Yoshida H., Goedert M.;
RT   "Phosphorylation of microtubule-associated protein tau by AMPK-related
RT   kinases.";
RL   J. Neurochem. 120:165-176(2012).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-519; THR-548; SER-552;
RP   SER-713 AND SER-721, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   INTERACTION WITH MARK1; MARK2; MARK3 AND MARK4, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION AT SER-579.
RX   PubMed=23666762; DOI=10.1007/s12017-013-8232-3;
RA   Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G.,
RA   Landegren U., Sunnemark D., Kamali-Moghaddam M.;
RT   "Role of individual MARK isoforms in phosphorylation of tau at Ser262 in
RT   Alzheimer's disease.";
RL   NeuroMolecular Med. 15:458-469(2013).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-519, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   INTERACTION WITH LRRK2, AND SUBCELLULAR LOCATION.
RX   PubMed=26014385; DOI=10.1007/s12035-015-9209-z;
RA   Guerreiro P.S., Gerhardt E., Lopes da Fonseca T., Baehr M., Outeiro T.F.,
RA   Eckermann K.;
RT   "LRRK2 Promotes Tau Accumulation, Aggregation and Release.";
RL   Mol. Neurobiol. 53:3124-3135(2016).
RN   [47]
RP   INTERACTION WITH LRP1.
RX   PubMed=32296178; DOI=10.1038/s41586-020-2156-5;
RA   Rauch J.N., Luna G., Guzman E., Challis C., Sibih Y.E., Leshuk C.,
RA   Hernandez I., Wegmann S., Hyman B.T., Gradinaru V., Kampmann M.,
RA   Kosik K.S.;
RT   "LRP1 is a master regulator of tau uptake and spread.";
RL   Nature 580:381-385(2020).
RN   [48]
RP   STRUCTURE BY NMR OF 542-554 IN COMPLEX WITH PIN1.
RX   PubMed=11313338; DOI=10.1074/jbc.m010327200;
RA   Wintjens R., Wieruszeski J.-M., Drobecq H., Rousselot-Pailley P., Buee L.,
RA   Lippens G., Landrieu I.;
RT   "1H NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine
RT   peptides.";
RL   J. Biol. Chem. 276:25150-25156(2001).
RN   [49]
RP   SUBCELLULAR LOCATION.
RX   PubMed=32272059; DOI=10.1016/j.cell.2020.03.031;
RA   Zhang M., Liu L., Lin X., Wang Y., Li Y., Guo Q., Li S., Sun Y., Tao X.,
RA   Zhang D., Lv X., Zheng L., Ge L.;
RT   "A Translocation Pathway for Vesicle-Mediated Unconventional Protein
RT   Secretion.";
RL   Cell 181:637-652(2020).
RN   [50]
RP   REVIEW ON VARIANTS.
RX   PubMed=10899436; DOI=10.1016/s0925-4439(00)00037-5;
RA   Goedert M., Spillantini M.G.;
RT   "Tau mutations in frontotemporal dementia FTDP-17 and their relevance for
RT   Alzheimer's disease.";
RL   Biochim. Biophys. Acta 1502:110-121(2000).
RN   [51]
RP   VARIANT FTD1 MET-654, VARIANTS ASN-285; ALA-289; HIS-441 AND PRO-447, AND
RP   INVOLVEMENT IN FTD1.
RX   PubMed=9629852; DOI=10.1002/ana.410430617;
RA   Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L.,
RA   Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D.;
RT   "Tau is a candidate gene for chromosome 17 frontotemporal dementia.";
RL   Ann. Neurol. 43:815-825(1998).
RN   [52]
RP   ERRATUM OF PUBMED:9629852.
RA   Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L.,
RA   Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D.;
RL   Ann. Neurol. 44:428-428(1998).
RN   [53]
RP   VARIANT FTD1 LEU-618.
RX   PubMed=9736786; DOI=10.1093/hmg/7.11.1825;
RA   Dumanchin C., Camuzat A., Campion D., Verpillat P., Hannequin D.,
RA   Dubois B., Saugier-Veber P., Martin C., Penet C., Charbonnier F., Agid Y.,
RA   Frebourg T., Brice A.;
RT   "Segregation of a missense mutation in the microtubule-associated protein
RT   tau gene with familial frontotemporal dementia and parkinsonism.";
RL   Hum. Mol. Genet. 7:1825-1829(1998).
RN   [54]
RP   VARIANTS FTD1 VAL-589; LEU-618 AND TRP-723.
RX   PubMed=9641683; DOI=10.1038/31508;
RA   Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H.,
RA   Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J.,
RA   Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M.,
RA   de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M.,
RA   Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A.,
RA   Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F.,
RA   Tannenberg T., Dodd P.R., Hayward N., Kwok J.B.J., Schofield P.R.,
RA   Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A.,
RA   Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P.;
RT   "Association of missense and 5'-splice-site mutations in tau with the
RT   inherited dementia FTDP-17.";
RL   Nature 393:702-705(1998).
RN   [55]
RP   VARIANTS FTD1 LYS-596 AND LEU-618.
RX   PubMed=9789048; DOI=10.1073/pnas.95.22.13103;
RA   Clark L.N., Poorkaj P., Wszolek Z., Geschwind D.H., Nasreddine Z.S.,
RA   Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A.,
RA   D'Souza I., Lee V.M.-Y., Reed L., Trojanowski J.Q., Zhukareva V., Bird T.,
RA   Schellenberg G., Wilhelmsen K.C.;
RT   "Pathogenic implications of mutations in the tau gene in pallido-ponto-
RT   nigral degeneration and related neurodegenerative disorders linked to
RT   chromosome 17.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13103-13107(1998).
RN   [56]
RP   VARIANT PPND LYS-596.
RX   PubMed=10412802; DOI=10.1007/s004010051052;
RA   Delisle M.-B., Murrell J.R., Richardson R., Trofatter J.A., Rascol O.,
RA   Soulages X., Mohr M., Calvas P., Ghetti B.;
RT   "A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a
RT   tauopathy with dementia and supranuclear palsy.";
RL   Acta Neuropathol. 98:62-77(1999).
RN   [57]
RP   VARIANTS FTD1 VAL-589; LYS-597 DEL; LEU-618 AND TRP-723.
RX   PubMed=9973279; DOI=10.1086/302256;
RA   Rizzu P., Van Swieten J.C., Joosse M., Hasegawa M., Stevens M., Tibben A.,
RA   Niermeijer M.F., Hillebrand M., Ravid R., Oostra B.A., Goedert M.,
RA   van Duijn C.M., Heutink P.;
RT   "High prevalence of mutations in the microtubule-associated protein tau in
RT   a population study of frontotemporal dementia in the Netherlands.";
RL   Am. J. Hum. Genet. 64:414-421(1999).
RN   [58]
RP   VARIANT FTD1 SER-618.
RX   PubMed=10553987;
RX   DOI=10.1002/1531-8249(199911)46:5<708::aid-ana5>3.0.co;2-k;
RA   Sperfeld A.D., Collatz M.B., Baier H., Palmbach M., Storch A., Schwarz J.,
RA   Tatsch K., Reske S., Joosse M., Heutink P., Ludolph A.C.;
RT   "FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures
RT   caused by a novel mutation.";
RL   Ann. Neurol. 46:708-715(1999).
RN   [59]
RP   VARIANTS FTD1 LEU-618; MET-654 AND TRP-723.
RX   PubMed=10214944; DOI=10.1016/s0014-5793(99)00294-x;
RA   Nacharaju P., Lewis J., Easson C., Yen S., Hackett J., Hutton M., Yen S.H.;
RT   "Accelerated filament formation from tau protein with specific FTDP-17
RT   missense mutations.";
RL   FEBS Lett. 447:195-199(1999).
RN   [60]
RP   VARIANT FTD1/CBD SER-618.
RX   PubMed=10374757; DOI=10.1097/00005072-199906000-00011;
RA   Bugiani O., Murrell J.R., Giaccone G., Hasegawa M., Ghigo G., Tabaton M.,
RA   Morbin M., Primavera A., Carella F., Solaro C., Grisoli M., Savoiardo M.,
RA   Spillantini M.G., Tagliavini F., Goedert M., Ghetti B.;
RT   "Frontotemporal dementia and corticobasal degeneration in a family with a
RT   P301S mutation in tau.";
RL   J. Neuropathol. Exp. Neurol. 58:667-677(1999).
RN   [61]
RP   VARIANT PIDB ARG-706.
RX   PubMed=10604746; DOI=10.1097/00005072-199912000-00002;
RA   Murrell J.R., Spillantini M.G., Zolo P., Guazzelli M., Smith M.J.,
RA   Hasegawa M., Redi F., Crowther R.A., Pietrini P., Ghetti B., Goedert M.;
RT   "Tau gene mutation G389R causes a tauopathy with abundant pick body-like
RT   inclusions and axonal deposits.";
RL   J. Neuropathol. Exp. Neurol. 58:1207-1226(1999).
RN   [62]
RP   VARIANT FTD1 LYS-596.
RX   PubMed=10489057; DOI=10.1212/wnl.53.4.864;
RA   Yasuda M., Kawamata T., Komure O., Kuno S., D'Souza I., Poorkaj P.,
RA   Kawai J., Tanimukai S., Yamamoto Y., Hasegawa H., Sasahara M., Hazama F.,
RA   Schellenberg G.D., Tanaka C.;
RT   "A mutation in the microtubule-associated protein tau in pallido-nigro-
RT   luysian degeneration.";
RL   Neurology 53:864-868(1999).
RN   [63]
RP   VARIANTS PSNP1 ASN-285 AND ALA-289.
RX   PubMed=10534245; DOI=10.1212/wnl.53.7.1421;
RA   Higgins J.J., Adler R.L., Loveless J.M.;
RT   "Mutational analysis of the tau gene in progressive supranuclear palsy.";
RL   Neurology 53:1421-1424(1999).
RN   [64]
RP   VARIANT FTD1 ASN-622.
RX   PubMed=10208578; DOI=10.1097/00001756-199902250-00010;
RA   Iijima M., Tabira T., Poorkaj P., Schellenberg G.D., Trojanowski J.Q.,
RA   Lee V.M.-Y., Schmidt M.L., Takahashi K., Nabika T., Matsumoto T.,
RA   Yamashita Y., Yoshioka S., Ishino H.;
RT   "A distinct familial presenile dementia with a novel missense mutation in
RT   the tau gene.";
RL   NeuroReport 10:497-501(1999).
RN   [65]
RP   VARIANT FTD1 VAL-659.
RX   PubMed=11117541;
RX   DOI=10.1002/1531-8249(200012)48:6<850::aid-ana5>3.3.co;2-m;
RA   Lippa C.F., Zhukareva V., Kawarai T., Uryu K., Shafiq M., Nee L.E.,
RA   Grafman J., Liang Y., St George-Hyslop P.H., Trojanowski J.Q., Lee V.M.-Y.;
RT   "Frontotemporal dementia with novel tau pathology and a Glu342Val tau
RT   mutation.";
RL   Ann. Neurol. 48:850-858(2000).
RN   [66]
RP   VARIANTS PIDB THR-574 AND ARG-706, AND CHARACTERIZATION OF VARIANTS PIDB
RP   THR-574 AND ARG-706.
RX   PubMed=11117542;
RX   DOI=10.1002/1531-8249(200012)48:6<859::aid-ana6>3.3.co;2-t;
RA   Pickering-Brown S., Baker M., Yen S.-H., Liu W.-K., Hasegawa M., Cairns N.,
RA   Lantos P.L., Rossor M., Iwatsubo T., Davies Y., Allsop D., Furlong R.,
RA   Owen F., Hardy J., Mann D., Hutton M.;
RT   "Pick's disease is associated with mutations in the tau gene.";
RL   Ann. Neurol. 48:859-867(2000).
RN   [67]
RP   VARIANT PIDB THR-574.
RX   PubMed=11089577; DOI=10.1093/jnen/59.11.990;
RA   Rizzini C., Goedert M., Hodges J.R., Smith M.J., Jakes R., Hills R.,
RA   Xuereb J.H., Crowther R.A., Spillantini M.G.;
RT   "Tau gene mutation K257T causes a tauopathy similar to Pick's disease.";
RL   J. Neuropathol. Exp. Neurol. 59:990-1001(2000).
RN   [68]
RP   VARIANT FTD1 LYS-596.
RX   PubMed=10802785; DOI=10.1212/wnl.54.9.1787;
RA   Arima K., Kowalska A., Hasegawa M., Mukoyama M., Watanabe R., Kawai M.,
RA   Takahashi K., Iwatsubo T., Tabira T., Sunohara N.;
RT   "Two brothers with frontotemporal dementia and parkinsonism with an N279K
RT   mutation of the tau gene.";
RL   Neurology 54:1787-1795(2000).
RN   [69]
RP   VARIANT FTD1 SER-618.
RX   PubMed=11071507; DOI=10.1212/wnl.55.8.1224;
RA   Yasuda M., Yokoyama K., Nakayasu T., Nishimura Y., Matsui M., Yokoyama T.,
RA   Miyoshi K., Tanaka C.;
RT   "A Japanese patient with frontotemporal dementia and parkinsonism by a tau
RT   P301S mutation.";
RL   Neurology 55:1224-1227(2000).
RN   [70]
RP   VARIANT FTD1 HIS-613.
RX   PubMed=11585254; DOI=10.1007/s004010000333;
RA   Iseki E., Matsumura T., Marui W., Hino H., Odawara T., Sugiyama N.,
RA   Suzuki K., Sawada H., Arai T., Kosaka K.;
RT   "Familial frontotemporal dementia and parkinsonism with a novel N296H
RT   mutation in exon 10 of the tau gene and a widespread tau accumulation in
RT   the glial cells.";
RL   Acta Neuropathol. 102:285-292(2001).
RN   [71]
RP   VARIANT PSNP1 ASN-613 DEL.
RX   PubMed=11220749;
RX   DOI=10.1002/1531-8249(20010201)49:2<263::aid-ana50>3.0.co;2-k;
RA   Pastor P., Pastor E., Carnero C., Vela R., Garcia T., Amer G., Tolosa E.,
RA   Oliva R.;
RT   "Familial atypical progressive supranuclear palsy associated with
RT   homozygosity for the delN296 mutation in the tau gene.";
RL   Ann. Neurol. 49:263-267(2001).
RN   [72]
RP   VARIANT PIDB ILE-686, AND CHARACTERIZATION OF VARIANT PIDB ILE-686.
RX   PubMed=11601501; DOI=10.1002/ana.1223;
RA   Neumann M., Schulz-Schaeffer W., Crowther R.A., Smith M.J.,
RA   Spillantini M.G., Goedert M., Kretzschmar H.A.;
RT   "Pick's disease associated with the novel Tau gene mutation K369I.";
RL   Ann. Neurol. 50:503-513(2001).
RN   [73]
RP   CHARACTERIZATION OF VARIANT FTD1 TRP-723.
RX   PubMed=11278002; DOI=10.1016/s0014-5793(01)02267-0;
RA   Connell J.W., Gibb G.M., Betts J.C., Blackstock W.P., Gallo J.-M.,
RA   Lovestone S., Hutton M., Anderton B.H.;
RT   "Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by
RT   glycogen synthase kinase 3beta identified by mass spectrometry demonstrate
RT   certain mutations exert long-range conformational changes.";
RL   FEBS Lett. 493:40-44(2001).
RN   [74]
RP   VARIANT FTD1 LYS-596.
RX   PubMed=12473774; DOI=10.1212/01.wnl.0000038909.49164.4b;
RA   Tsuboi Y., Baker M., Hutton M.L., Uitti R.J., Rascol O., Delisle M.-B.,
RA   Soulages X., Murrell J.R., Ghetti B., Yasuda M., Komure O., Kuno S.,
RA   Arima K., Sunohara N., Kobayashi T., Mizuno Y., Wszolek Z.K.;
RT   "Clinical and genetic studies of families with the tau N279K mutation
RT   (FTDP-17).";
RL   Neurology 59:1791-1793(2002).
RN   [75]
RP   VARIANT PIDB PHE-637, AND CHARACTERIZATION OF VARIANT PIDB PHE-637.
RX   PubMed=11891833; DOI=10.1002/ana.10140;
RA   Rosso S.M., Van Herpen E., Deelen W., Kamphorst W., Severijnen L.-A.,
RA   Willemsen R., Ravid R., Niermeijer M.F., Dooijes D., Smith M.J.,
RA   Goedert M., Heutink P., Van Swieten J.C.;
RT   "A novel tau mutation, S320F, causes a tauopathy with inclusions similar to
RT   those in Pick's disease.";
RL   Ann. Neurol. 51:373-376(2002).
RN   [76]
RP   VARIANT FTD1 HIS-5, AND CHARACTERIZATION OF VARIANT FTD1 HIS-5.
RX   PubMed=11921059; DOI=10.1002/ana.10163;
RA   Hayashi S., Toyoshima Y., Hasegawa M., Umeda Y., Wakabayashi K.,
RA   Tokiguchi S., Iwatsubo T., Takahashi H.;
RT   "Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene
RT   mutation.";
RL   Ann. Neurol. 51:525-530(2002).
RN   [77]
RP   VARIANT PSNP1 LEU-5, AND CHARACTERIZATION OF VARIANT PSNP1 LEU-5.
RX   PubMed=12325083; DOI=10.1002/ana.10340;
RA   Poorkaj P., Muma N.A., Zhukareva V., Cochran E.J., Shannon K.M., Hurtig H.,
RA   Koller W.C., Bird T.D., Trojanowski J.Q., Lee V.M.-Y., Schellenberg G.D.;
RT   "An R5L tau mutation in a subject with a progressive supranuclear palsy
RT   phenotype.";
RL   Ann. Neurol. 52:511-516(2002).
RN   [78]
RP   CHARACTERIZATION OF VARIANTS FTD1 ASN-613 DEL AND HIS-613.
RX   PubMed=11906000; DOI=10.1046/j.0022-3042.2001.00729.x;
RA   Yoshida H., Crowther R.A., Goedert M.;
RT   "Functional effects of tau gene mutations deltaN296 and N296H.";
RL   J. Neurochem. 80:548-551(2002).
RN   [79]
RP   VARIANT FTD1 TRP-723.
RX   PubMed=11889249; DOI=10.1212/wnl.58.5.811;
RA   Saito Y., Geyer A., Sasaki R., Kuzuhara S., Nanba E., Miyasaka T.,
RA   Suzuki K., Murayama S.;
RT   "Early-onset, rapidly progressive familial tauopathy with R406W mutation.";
RL   Neurology 58:811-813(2002).
RN   [80]
RP   VARIANT FTD1 VAL-583, AND CHARACTERIZATION OF VARIANT FTD1 VAL-583.
RX   PubMed=12509859; DOI=10.1002/ana.10447;
RA   Kobayashi T., Ota S., Tanaka K., Ito Y., Hasegawa M., Umeda Y., Motoi Y.,
RA   Takanashi M., Yasuhara M., Anno M., Mizuno Y., Mori H.;
RT   "A novel L266V mutation of the tau gene causes frontotemporal dementia with
RT   a unique tau pathology.";
RL   Ann. Neurol. 53:133-137(2003).
RN   [81]
RP   VARIANT FATAL RESPIRATORY HYPOVENTILATION LEU-669, AND CHARACTERIZATION OF
RP   VARIANT FATAL RESPIRATORY HYPOVENTILATION LEU-669.
RX   PubMed=14595660; DOI=10.1002/ana.10747;
RA   Nicholl D.J., Greenstone M.A., Clarke C.E., Rizzu P., Crooks D., Crowe A.,
RA   Trojanowski J.Q., Lee V.M.-Y., Heutink P.;
RT   "An English kindred with a novel recessive tauopathy and respiratory
RT   failure.";
RL   Ann. Neurol. 54:682-686(2003).
RN   [82]
RP   VARIANT FTD1/ALZHEIMER DISEASE TRP-723, AND INVOLVEMENT IN ALZHEIMER
RP   DISEASE.
RX   PubMed=14517953; DOI=10.1002/humu.10269;
RA   Rademakers R., Dermaut B., Peeters K., Cruts M., Heutink P., Goate A.,
RA   Van Broeckhoven C.;
RT   "Tau (MAPT) mutation arg406trp presenting clinically with Alzheimer disease
RT   does not share a common founder in western Europe.";
RL   Hum. Mutat. 22:409-411(2003).
RN   [83]
RP   VARIANT ATYPICAL PSNP1 ASN-613 DEL.
RX   PubMed=14991829; DOI=10.1002/ana.20006;
RA   Rossi G., Gasparoli E., Pasquali C., Di Fede G., Testa D., Albanese A.,
RA   Bracco F., Tagliavini F.;
RT   "Progressive supranuclear palsy and Parkinson's disease in a family with a
RT   new mutation in the tau gene.";
RL   Ann. Neurol. 55:448-448(2004).
RN   [84]
RP   VARIANT PSNP1/ATYPICAL PSNP1 ASN-613 DEL.
RX   PubMed=14991828; DOI=10.1002/ana.20025;
RA   Oliva R., Pastor P.;
RT   "Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear
RT   palsy.";
RL   Ann. Neurol. 55:448-449(2004).
RN   [85]
RP   VARIANT FTD1 SER-618.
RX   PubMed=16240366; DOI=10.1002/ana.20668;
RA   Yasuda M., Nakamura Y., Kawamata T., Kaneyuki H., Maeda K., Komure O.;
RT   "Phenotypic heterogeneity within a new family with the MAPT P301S
RT   mutation.";
RL   Ann. Neurol. 58:920-928(2005).
RN   [86]
RP   VARIANT PSNP1 VAL-620.
RX   PubMed=16157753; DOI=10.1001/archneur.62.9.1444;
RA   Ros R., Thobois S., Streichenberger N., Kopp N., Sanchez M.P., Perez M.,
RA   Hoenicka J., Avila J., Honnorat J., de Yebenes J.G.;
RT   "A new mutation of the tau gene, G303V, in early-onset familial progressive
RT   supranuclear palsy.";
RL   Arch. Neurol. 62:1444-1450(2005).
RN   [87]
RP   VARIANT FTD1 MET-634.
RX   PubMed=15883319; DOI=10.1212/01.wnl.0000160116.65034.12;
RA   Zarranz J.J., Ferrer I., Lezcano E., Forcadas M.I., Eizaguirre B.,
RA   Atares B., Puig B., Gomez-Esteban J.C., Fernandez-Maiztegui C., Rouco I.,
RA   Perez-Concha T., Fernandez M., Rodriguez O., Rodriguez-Martinez A.B.,
RA   de Pancorbo M.M., Pastor P., Perez-Tur J.;
RT   "A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron
RT   disease.";
RL   Neurology 64:1578-1585(2005).
RN   [88]
RP   VARIANTS MET-17; ALA-30 AND ILE-617.
RX   PubMed=20020531; DOI=10.1002/humu.21152;
RA   Guerreiro R.J., Washecka N., Hardy J., Singleton A.;
RT   "A thorough assessment of benign genetic variability in GRN and MAPT.";
RL   Hum. Mutat. 31:E1126-E1140(2010).
RN   [89]
RP   VARIANT FTD1/ALZHEIMER DISEASE TRP-723.
RX   PubMed=26086902; DOI=10.1016/j.gene.2015.06.033;
RA   Behnam M., Ghorbani F., Shin J.H., Kim D.S., Jang H., Nouri N., Sedghi M.,
RA   Salehi M., Ansari B., Basiri K.;
RT   "Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance
RT   of a unique mutation.";
RL   Gene 570:150-152(2015).
RN   [90]
RP   VARIANT FTD1 ARG-590, CHARACTERIZATION OF VARIANT FTD1 ARG-590, AND
RP   FUNCTION.
RX   PubMed=32961270; DOI=10.1016/j.nbd.2020.105079;
RA   Sandberg A., Ling H., Gearing M., Dombroski B., Cantwell L., R'Bibo L.,
RA   Levey A., Schellenberg G.D., Hardy J., Wood N., Fernius J., Nystroem S.,
RA   Svensson S., Thor S., Hammarstroem P., Revesz T., Mok K.Y.;
RT   "Fibrillation and molecular characteristics are coherent with clinical and
RT   pathological features of 4-repeat tauopathy caused by MAPT variant G273R.";
RL   Neurobiol. Dis. 146:105079-105079(2020).
CC   -!- FUNCTION: Promotes microtubule assembly and stability, and might be
CC       involved in the establishment and maintenance of neuronal polarity
CC       (PubMed:21985311). The C-terminus binds axonal microtubules while the
CC       N-terminus binds neural plasma membrane components, suggesting that tau
CC       functions as a linker protein between both (PubMed:21985311,
CC       PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT
CC       localization (in the neuronal cell) in the domain of the cell body
CC       defined by the centrosome. The short isoforms allow plasticity of the
CC       cytoskeleton whereas the longer isoforms may preferentially play a role
CC       in its stabilization. {ECO:0000269|PubMed:21985311,
CC       ECO:0000269|PubMed:32961270}.
CC   -!- SUBUNIT: Interacts with MARK1, MARK2, MARK3 and MARK4
CC       (PubMed:23666762). Interacts with PSMC2 through SQSTM1 (By similarity).
CC       Interacts with SQSTM1 when polyubiquitinated (PubMed:15953362).
CC       Interacts with FKBP4 (By similarity). Binds to CSNK1D
CC       (PubMed:14761950). Interacts with SGK1 (PubMed:16982696). Interacts
CC       with EPM2A; the interaction dephosphorylates MAPT at Ser-396
CC       (PubMed:19542233). Interacts with PIN1 (PubMed:11313338). Interacts
CC       with LRRK2 (PubMed:26014385). Interacts with LRP1, leading to
CC       endocytosis; this interaction is reduced in the presence of LRPAP1/RAP
CC       (PubMed:32296178). {ECO:0000250|UniProtKB:P10637,
CC       ECO:0000250|UniProtKB:P19332, ECO:0000269|PubMed:11313338,
CC       ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15953362,
CC       ECO:0000269|PubMed:16982696, ECO:0000269|PubMed:19542233,
CC       ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:26014385,
CC       ECO:0000269|PubMed:32296178}.
CC   -!- INTERACTION:
CC       P10636; P31749: AKT1; NbExp=2; IntAct=EBI-366182, EBI-296087;
CC       P10636; PRO_0000001987 [P02649]: APOE; NbExp=3; IntAct=EBI-366182, EBI-9209835;
CC       P10636; P05067: APP; NbExp=8; IntAct=EBI-366182, EBI-77613;
CC       P10636; PRO_0000000092 [P05067]: APP; NbExp=5; IntAct=EBI-366182, EBI-821758;
CC       P10636; Q9HC96: CAPN10; NbExp=3; IntAct=EBI-366182, EBI-3915761;
CC       P10636; Q9NR30: DDX21; NbExp=3; IntAct=EBI-366182, EBI-357942;
CC       P10636; O43583: DENR; NbExp=2; IntAct=EBI-366182, EBI-716083;
CC       P10636; Q92608-2: DOCK2; NbExp=3; IntAct=EBI-366182, EBI-25875570;
CC       P10636; P06241: FYN; NbExp=3; IntAct=EBI-366182, EBI-515315;
CC       P10636; P49841: GSK3B; NbExp=4; IntAct=EBI-366182, EBI-373586;
CC       P10636; P11142: HSPA8; NbExp=6; IntAct=EBI-366182, EBI-351896;
CC       P10636; Q8TCE9: LGALS14; NbExp=3; IntAct=EBI-366182, EBI-10274069;
CC       P10636; Q9UPY8: MAPRE3; NbExp=3; IntAct=EBI-366182, EBI-726739;
CC       P10636; P10636: MAPT; NbExp=3; IntAct=EBI-366182, EBI-366182;
CC       P10636; P04156: PRNP; NbExp=2; IntAct=EBI-366182, EBI-977302;
CC       P10636; P46779: RPL28; NbExp=4; IntAct=EBI-366182, EBI-366357;
CC       P10636; P43004: SLC1A2; NbExp=4; IntAct=EBI-366182, EBI-3440986;
CC       P10636; Q9UNE7: STUB1; NbExp=2; IntAct=EBI-366182, EBI-357085;
CC       P10636; Q9UNE7-1: STUB1; NbExp=5; IntAct=EBI-366182, EBI-15687717;
CC       P10636; O15195-2: VILL; NbExp=3; IntAct=EBI-366182, EBI-21845957;
CC       P10636; P63104: YWHAZ; NbExp=8; IntAct=EBI-366182, EBI-347088;
CC       P10636; Q9C0A1: ZFHX2; NbExp=3; IntAct=EBI-366182, EBI-25850811;
CC       P10636-2; P06241: FYN; NbExp=2; IntAct=EBI-7796412, EBI-515315;
CC       P10636-2; Q5S007: LRRK2; NbExp=3; IntAct=EBI-7796412, EBI-5323863;
CC       P10636-2; P31947: SFN; NbExp=2; IntAct=EBI-7796412, EBI-476295;
CC       P10636-2; P63104: YWHAZ; NbExp=2; IntAct=EBI-7796412, EBI-347088;
CC       P10636-3; P63104: YWHAZ; NbExp=9; IntAct=EBI-7145070, EBI-347088;
CC       P10636-5; P06241: FYN; NbExp=2; IntAct=EBI-21313635, EBI-515315;
CC       P10636-6; P02649: APOE; NbExp=3; IntAct=EBI-7796455, EBI-1222467;
CC       P10636-6; Q14203-5: DCTN1; NbExp=3; IntAct=EBI-7796455, EBI-25840379;
CC       P10636-6; Q92608-2: DOCK2; NbExp=3; IntAct=EBI-7796455, EBI-25875570;
CC       P10636-6; P06241: FYN; NbExp=3; IntAct=EBI-7796455, EBI-515315;
CC       P10636-6; P11142: HSPA8; NbExp=3; IntAct=EBI-7796455, EBI-351896;
CC       P10636-6; O60260-5: PRKN; NbExp=3; IntAct=EBI-7796455, EBI-21251460;
CC       P10636-6; P37840: SNCA; NbExp=3; IntAct=EBI-7796455, EBI-985879;
CC       P10636-6; Q9C0A1: ZFHX2; NbExp=3; IntAct=EBI-7796455, EBI-25850811;
CC       P10636-7; O00499-1: BIN1; NbExp=5; IntAct=EBI-6926270, EBI-6926280;
CC       P10636-8; P07355: ANXA2; NbExp=10; IntAct=EBI-366233, EBI-352622;
CC       P10636-8; P08133: ANXA6; NbExp=5; IntAct=EBI-366233, EBI-352541;
CC       P10636-8; P05067: APP; NbExp=4; IntAct=EBI-366233, EBI-77613;
CC       P10636-8; O00499-1: BIN1; NbExp=6; IntAct=EBI-366233, EBI-6926280;
CC       P10636-8; Q14203: DCTN1; NbExp=9; IntAct=EBI-366233, EBI-724352;
CC       P10636-8; P26196: DDX6; NbExp=10; IntAct=EBI-366233, EBI-351257;
CC       P10636-8; Q02790: FKBP4; NbExp=7; IntAct=EBI-366233, EBI-1047444;
CC       P10636-8; Q13451: FKBP5; NbExp=8; IntAct=EBI-366233, EBI-306914;
CC       P10636-8; P06241: FYN; NbExp=9; IntAct=EBI-366233, EBI-515315;
CC       P10636-8; P49840: GSK3A; NbExp=2; IntAct=EBI-366233, EBI-1044067;
CC       P10636-8; P49841: GSK3B; NbExp=12; IntAct=EBI-366233, EBI-373586;
CC       P10636-8; P08238: HSP90AB1; NbExp=18; IntAct=EBI-366233, EBI-352572;
CC       P10636-8; P14625: HSP90B1; NbExp=5; IntAct=EBI-366233, EBI-359129;
CC       P10636-8; Q92743: HTRA1; NbExp=9; IntAct=EBI-366233, EBI-352256;
CC       P10636-8; Q5S007: LRRK2; NbExp=9; IntAct=EBI-366233, EBI-5323863;
CC       P10636-8; P10636-8: MAPT; NbExp=6; IntAct=EBI-366233, EBI-366233;
CC       P10636-8; O43347: MSI1; NbExp=2; IntAct=EBI-366233, EBI-726515;
CC       P10636-8; Q96DH6: MSI2; NbExp=4; IntAct=EBI-366233, EBI-2462339;
CC       P10636-8; P07237: P4HB; NbExp=6; IntAct=EBI-366233, EBI-395883;
CC       P10636-8; Q12765: SCRN1; NbExp=5; IntAct=EBI-366233, EBI-2690712;
CC       P10636-8; P37840: SNCA; NbExp=12; IntAct=EBI-366233, EBI-985879;
CC       P10636-8; Q71U36: TUBA1A; NbExp=7; IntAct=EBI-366233, EBI-302552;
CC       P10636-8; P07437: TUBB; NbExp=4; IntAct=EBI-366233, EBI-350864;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10747907,
CC       ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:26014385}. Cell
CC       membrane {ECO:0000269|PubMed:10747907}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10747907}; Cytoplasmic side
CC       {ECO:0000269|PubMed:10747907}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:10747907}. Cell projection, axon
CC       {ECO:0000269|PubMed:10747907}. Cell projection, dendrite
CC       {ECO:0000269|PubMed:23666762}. Secreted {ECO:0000269|PubMed:32272059}.
CC       Note=Mostly found in the axons of neurons, in the cytosol and in
CC       association with plasma membrane components (PubMed:10747907). Can be
CC       secreted; the secretion is dependent on protein unfolding and
CC       facilitated by the cargo receptor TMED10; it results in protein
CC       translocation from the cytoplasm into the ERGIC (endoplasmic reticulum-
CC       Golgi intermediate compartment) followed by vesicle entry and secretion
CC       (PubMed:32272059). {ECO:0000269|PubMed:10747907,
CC       ECO:0000269|PubMed:32272059}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC         Comment=Additional isoforms seem to exist. Isoforms differ from each
CC         other by the presence or absence of up to 5 of the 15 exons. One of
CC         these optional exons contains the additional tau/MAP repeat.;
CC       Name=PNS-tau;
CC         IsoId=P10636-1; Sequence=Displayed;
CC       Name=Fetal-tau; Synonyms=0N3R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-2; Sequence=VSP_003176, VSP_003177, VSP_003179,
CC                                  VSP_003180, VSP_003181;
CC       Name=Tau-A;
CC         IsoId=P10636-3; Sequence=VSP_003175, VSP_003176, VSP_003177,
CC                                  VSP_003178, VSP_003179, VSP_003180,
CC                                  VSP_003181;
CC       Name=Tau-B; Synonyms=1N3R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-4; Sequence=VSP_003177, VSP_003179, VSP_003180,
CC                                  VSP_003181;
CC       Name=Tau-C; Synonyms=Tau-3, 2N3R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-5; Sequence=VSP_003179, VSP_003180, VSP_003181;
CC       Name=Tau-D; Synonyms=0N4R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-6; Sequence=VSP_003176, VSP_003177, VSP_003179,
CC                                  VSP_003180;
CC       Name=Tau-E; Synonyms=1N4R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-7; Sequence=VSP_003177, VSP_003179, VSP_003180;
CC       Name=Tau-F; Synonyms=Tau-4, 2N4R {ECO:0000303|PubMed:9789048};
CC         IsoId=P10636-8; Sequence=VSP_003179, VSP_003180;
CC       Name=Tau-G;
CC         IsoId=P10636-9; Sequence=VSP_026780;
CC   -!- TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed
CC       in the peripheral nervous system while the others are expressed in the
CC       central nervous system.
CC   -!- DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressed in an
CC       adult-specific manner and is not found in fetal brain, whereas three-
CC       repeat (type I) TAU/MAPT is found in both adult and fetal brain.
CC   -!- DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoforms contain 3
CC       repeats while type II isoforms contain 4 repeats.
CC   -!- PTM: Phosphorylation at serine and threonine residues in S-P or T-P
CC       motifs by proline-directed protein kinases (PDPK1, CDK1, CDK5, GSK3,
CC       MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in
CC       mitosis, and in the form associated with paired helical filaments (PHF-
CC       tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule
CC       affinity-regulating kinase (MARK1, MARK2, MARK3 or MARK4), causing
CC       detachment from microtubules, and their disassembly (PubMed:23666762,
CC       PubMed:7706316). Phosphorylation decreases with age. Phosphorylation
CC       within tau/MAP's repeat domain or in flanking regions seems to reduce
CC       tau/MAP's interaction with, respectively, microtubules or plasma
CC       membrane components (PubMed:7706316). Phosphorylation on Ser-610, Ser-
CC       622, Ser-641 and Ser-673 in several isoforms during mitosis.
CC       Phosphorylation at Ser-548 by GSK3B reduces ability to bind and
CC       stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2
CC       in neurons affects ability to bind microtubules and plays a role in
CC       neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-
CC       606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates
CC       microtubule depolymerization and neurite formation in hippocampal
CC       neurons. There is a reciprocal down-regulation of phosphorylation and
CC       O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-
CC       GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-
CC       721 reduces glycosylation by a factor of 2 and 4 respectively.
CC       Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation
CC       on Ser-717. Dephosphorylated at several serine and threonine residues
CC       by the serine/threonine phosphatase PPP5C.
CC       {ECO:0000269|PubMed:14690523, ECO:0000269|PubMed:14761950,
CC       ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16443603,
CC       ECO:0000269|PubMed:16982696, ECO:0000269|PubMed:19451179,
CC       ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:21985311,
CC       ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:7706316,
CC       ECO:0000269|PubMed:8999860, ECO:0000269|PubMed:9614189}.
CC   -!- PTM: Polyubiquitinated. Requires functional TRAF6 and may provoke
CC       SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau
CC       can be modified by three different forms of polyubiquitination. 'Lys-
CC       48'-linked polyubiquitination is the major form, 'Lys-6'-linked and
CC       'Lys-11'-linked polyubiquitination also occur. {ECO:0000250,
CC       ECO:0000269|PubMed:15953362, ECO:0000269|PubMed:16443603}.
CC   -!- PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. There is
CC       reciprocal down-regulation of phosphorylation and O-GlcNAcylation.
CC       Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on
CC       this site, while phosphorylation on Ser-713 and Ser-721 reduces O-
CC       GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on
CC       Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.
CC       {ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:15546861,
CC       ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,
CC       ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189}.
CC   -!- PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is
CC       a non-enzymatic post-translational modification that involves a
CC       covalent linkage between a sugar and an amino group of a protein
CC       molecule forming ketoamine. Subsequent oxidation, fragmentation and/or
CC       cross-linking of ketoamine leads to the production of advanced
CC       glycation endproducts (AGES). Glycation may play a role in stabilizing
CC       PHF aggregation leading to tangle formation in AD.
CC   -!- DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton in the
CC       brain is progressively disrupted and replaced by tangles of paired
CC       helical filaments (PHF) and straight filaments, mainly composed of
CC       hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation
CC       is greatly reduced in Alzheimer disease brain cerebral cortex leading
CC       to an increase in TAU/MAPT phosphorylations.
CC       {ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:26086902}.
CC   -!- DISEASE: Frontotemporal dementia 1 (FTD1) [MIM:600274]: A form of
CC       dementia characterized by pathologic finding of frontotemporal lobar
CC       degeneration, presenile dementia with behavioral changes, deterioration
CC       of cognitive capacities and loss of memory. In some cases, parkinsonian
CC       symptoms are prominent. Neuropathological changes include
CC       frontotemporal atrophy often associated with atrophy of the basal
CC       ganglia, substantia nigra, amygdala. In most cases, protein tau
CC       deposits are found in glial cells and/or neurons.
CC       {ECO:0000269|PubMed:10208578, ECO:0000269|PubMed:10214944,
CC       ECO:0000269|PubMed:10374757, ECO:0000269|PubMed:10489057,
CC       ECO:0000269|PubMed:10553987, ECO:0000269|PubMed:10802785,
CC       ECO:0000269|PubMed:11071507, ECO:0000269|PubMed:11117541,
CC       ECO:0000269|PubMed:11278002, ECO:0000269|PubMed:11585254,
CC       ECO:0000269|PubMed:11889249, ECO:0000269|PubMed:11906000,
CC       ECO:0000269|PubMed:11921059, ECO:0000269|PubMed:12473774,
CC       ECO:0000269|PubMed:12509859, ECO:0000269|PubMed:14517953,
CC       ECO:0000269|PubMed:15883319, ECO:0000269|PubMed:16240366,
CC       ECO:0000269|PubMed:26086902, ECO:0000269|PubMed:32961270,
CC       ECO:0000269|PubMed:9629852, ECO:0000269|PubMed:9641683,
CC       ECO:0000269|PubMed:9736786, ECO:0000269|PubMed:9789048,
CC       ECO:0000269|PubMed:9973279}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Pick disease of the brain (PIDB) [MIM:172700]: A rare form of
CC       dementia pathologically defined by severe atrophy, neuronal loss and
CC       gliosis. It is characterized by the occurrence of tau-positive
CC       inclusions, swollen neurons (Pick cells) and argentophilic neuronal
CC       inclusions known as Pick bodies that disproportionally affect the
CC       frontal and temporal cortical regions. Clinical features include
CC       aphasia, apraxia, confusion, anomia, memory loss and personality
CC       deterioration. {ECO:0000269|PubMed:10604746,
CC       ECO:0000269|PubMed:11089577, ECO:0000269|PubMed:11117542,
CC       ECO:0000269|PubMed:11601501, ECO:0000269|PubMed:11891833}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Defects in MAPT are a cause of corticobasal degeneration
CC       (CBD). It is marked by extrapyramidal signs and apraxia and can be
CC       associated with memory loss. Neuropathologic features may overlap
CC       Alzheimer disease, progressive supranuclear palsy, and Parkinson
CC       disease.
CC   -!- DISEASE: Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]:
CC       Characterized by akinetic-rigid syndrome, supranuclear gaze palsy,
CC       pyramidal tract dysfunction, pseudobulbar signs and cognitive
CC       capacities deterioration. Neurofibrillary tangles and gliosis but no
CC       amyloid plaques are found in diseased brains. Most cases appear to be
CC       sporadic, with a significant association with a common haplotype
CC       including the MAPT gene and the flanking regions. Familial cases show
CC       an autosomal dominant pattern of transmission with incomplete
CC       penetrance; genetic analysis of a few cases showed the occurrence of
CC       tau mutations, including a deletion of Asn-613.
CC       {ECO:0000269|PubMed:10534245, ECO:0000269|PubMed:11220749,
CC       ECO:0000269|PubMed:12325083, ECO:0000269|PubMed:14991828,
CC       ECO:0000269|PubMed:14991829, ECO:0000269|PubMed:16157753}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Parkinson-dementia syndrome (PARDE) [MIM:260540]: A syndrome
CC       characterized by parkinsonism, tremor, rigidity, dementia,
CC       ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration
CC       occurs in the hippocampus, basal ganglia and brainstem nuclei. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Alzforum; Note=MAPT mutations;
CC       URL="https://www.alzforum.org/mutations/search?genes%255B%255D=348";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68 of
CC       March 2006;
CC       URL="https://www.proteinspotlight.org/back_issues/068";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry;
CC       URL="https://en.wikipedia.org/wiki/Tau_protein";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03778; AAA60615.1; -; mRNA.
DR   EMBL; X14474; CAA32636.1; -; mRNA.
DR   EMBL; AF047863; AAC04277.1; -; Genomic_DNA.
DR   EMBL; AF027491; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047856; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047857; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027492; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047858; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047859; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027494; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04277.1; JOINED; Genomic_DNA.
DR   EMBL; AF027491; AAC04278.1; -; Genomic_DNA.
DR   EMBL; AF027492; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF047863; AAC04278.1; JOINED; Genomic_DNA.
DR   EMBL; AF027491; AAC04279.1; -; Genomic_DNA.
DR   EMBL; AF047856; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047857; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027492; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027493; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047860; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047862; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027494; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027495; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF027496; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047863; AAC04279.1; JOINED; Genomic_DNA.
DR   EMBL; AF047861; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY730549; AAU45390.1; -; mRNA.
DR   EMBL; BT006772; AAP35418.1; -; mRNA.
DR   EMBL; AC004139; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010792; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217771; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217779; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000558; AAH00558.1; -; mRNA.
DR   EMBL; BC098281; AAH98281.1; -; mRNA.
DR   EMBL; BC099721; AAH99721.1; -; mRNA.
DR   EMBL; BC101936; AAI01937.1; -; mRNA.
DR   EMBL; BC114504; AAI14505.1; -; mRNA.
DR   EMBL; BC114948; AAI14949.1; -; mRNA.
DR   EMBL; AY526356; AAS17881.1; -; mRNA.
DR   EMBL; M25298; AAA57264.1; -; mRNA.
DR   EMBL; BN000503; CAG26750.1; -; mRNA.
DR   CCDS; CCDS11499.1; -. [P10636-8]
DR   CCDS; CCDS11500.1; -. [P10636-6]
DR   CCDS; CCDS11501.1; -. [P10636-1]
DR   CCDS; CCDS11502.1; -. [P10636-2]
DR   CCDS; CCDS45715.1; -. [P10636-9]
DR   CCDS; CCDS45716.1; -. [P10636-7]
DR   CCDS; CCDS56033.1; -. [P10636-5]
DR   CCDS; CCDS92347.1; -. [P10636-4]
DR   PIR; I52232; I52232.
DR   PIR; JS0370; QRHUT1.
DR   PIR; PN0001; QRHUT2.
DR   PIR; S26663; S26663.
DR   RefSeq; NP_001116538.2; NM_001123066.4. [P10636-9]
DR   RefSeq; NP_001116539.1; NM_001123067.4. [P10636-7]
DR   RefSeq; NP_001190180.1; NM_001203251.2. [P10636-4]
DR   RefSeq; NP_001190181.1; NM_001203252.2. [P10636-5]
DR   RefSeq; NP_001364197.1; NM_001377268.1. [P10636-2]
DR   RefSeq; NP_005901.2; NM_005910.5. [P10636-8]
DR   RefSeq; NP_058518.1; NM_016834.5. [P10636-6]
DR   RefSeq; NP_058519.3; NM_016835.5. [P10636-1]
DR   RefSeq; NP_058525.1; NM_016841.5. [P10636-2]
DR   PDB; 1I8H; NMR; -; A=542-554.
DR   PDB; 2MZ7; NMR; -; A=584-629.
DR   PDB; 2ON9; X-ray; 1.51 A; A/B=623-628.
DR   PDB; 3OVL; X-ray; 1.81 A; A=623-628.
DR   PDB; 4E0M; X-ray; 1.75 A; A/B/C/D=622-634.
DR   PDB; 4E0N; X-ray; 1.65 A; A/B/C/D=622-634.
DR   PDB; 4E0O; X-ray; 1.82 A; A/B/C/D=622-634.
DR   PDB; 4FL5; X-ray; 1.90 A; P/Q=527-536.
DR   PDB; 4GLR; X-ray; 1.90 A; A/B=541-557.
DR   PDB; 4NP8; X-ray; 1.51 A; A=623-628.
DR   PDB; 4TQE; X-ray; 1.60 A; A=532-547.
DR   PDB; 4Y32; X-ray; 1.70 A; C/D=528-534.
DR   PDB; 4Y3B; X-ray; 1.80 A; C/D=528-534.
DR   PDB; 4Y5I; X-ray; 1.40 A; F/G=528-534.
DR   PDB; 5DMG; X-ray; 2.50 A; P/X/Z=733-747.
DR   PDB; 5E2V; X-ray; 1.64 A; P=511-528.
DR   PDB; 5E2W; X-ray; 1.50 A; P=511-528.
DR   PDB; 5HF3; X-ray; 1.80 A; B=528-534.
DR   PDB; 5K7N; EM; 1.10 A; Z=623-628.
DR   PDB; 5MO3; X-ray; 1.69 A; A=615-628.
DR   PDB; 5MP1; X-ray; 3.10 A; A/B/E/I=615-628.
DR   PDB; 5MP3; X-ray; 2.75 A; C/D=609-638.
DR   PDB; 5MP5; X-ray; 2.31 A; I/J/K=615-628.
DR   PDB; 5N5A; NMR; -; A=571-607.
DR   PDB; 5N5B; NMR; -; A=609-636.
DR   PDB; 5NVB; NMR; -; A=571-585.
DR   PDB; 5O3L; EM; 3.40 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 5O3O; EM; 3.50 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 5O3T; EM; 3.40 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 5V5B; EM; 1.50 A; A=591-600.
DR   PDB; 5V5C; EM; 1.25 A; A=592-597.
DR   PDB; 5ZIA; X-ray; 2.60 A; C/F/J/N/Q/R=552-560.
DR   PDB; 5ZV3; X-ray; 2.09 A; A=52-71.
DR   PDB; 6BB4; X-ray; 2.10 A; P/Q/R=703-725.
DR   PDB; 6CVJ; EM; 3.20 A; D=514-717.
DR   PDB; 6CVN; EM; 3.90 A; D=514-717.
DR   PDB; 6DC8; X-ray; 1.80 A; P=696-725.
DR   PDB; 6DC9; X-ray; 3.00 A; P/Q=696-725.
DR   PDB; 6DCA; X-ray; 2.60 A; P/Q/R/S=696-725.
DR   PDB; 6FBW; X-ray; 1.45 A; B/D=528-533.
DR   PDB; 6FI5; X-ray; 1.70 A; B=529-533.
DR   PDB; 6GK7; X-ray; 2.95 A; A=625-635.
DR   PDB; 6GK8; X-ray; 2.85 A; I=52-71.
DR   PDB; 6GX5; EM; 3.20 A; A/B/C=602-695.
DR   PDB; 6H06; X-ray; 2.63 A; G/I/J/K=721-746.
DR   PDB; 6HRE; EM; 3.20 A; A/B/C/D/E/F=1-758.
DR   PDB; 6HRF; EM; 3.30 A; A/B/C/D/E/F=1-758.
DR   PDB; 6LRA; X-ray; 1.90 A; C=592-597.
DR   PDB; 6N4P; X-ray; 1.85 A; A/C=5-10.
DR   PDB; 6NK4; EM; 1.99 A; A=591-599.
DR   PDB; 6NWP; EM; 2.30 A; A/B/C/D/E/F=1-758.
DR   PDB; 6NWQ; EM; 3.40 A; A/B/C/D/E/F=1-758.
DR   PDB; 6ODG; X-ray; 1.00 A; A/B=622-627.
DR   PDB; 6PXR; X-ray; 1.56 A; A=15-22.
DR   PDB; 6QJH; EM; 3.30 A; A/B/C=589-647.
DR   PDB; 6QJM; EM; 3.30 A; A/B/C=591-638.
DR   PDB; 6QJP; EM; 3.50 A; A/B/C=591-638.
DR   PDB; 6QJQ; EM; 3.70 A; A/B/C/D/E/F=620-647.
DR   PDB; 6TJO; EM; 3.20 A; A/B/C=1-758.
DR   PDB; 6TJX; EM; 3.00 A; A/B/C/D/E/F=1-758.
DR   PDB; 6VH7; EM; 3.80 A; A/B/C/E/F/G=591-697.
DR   PDB; 6VHA; EM; 4.30 A; E/F/G=591-697.
DR   PDB; 6VHL; EM; 3.30 A; E/F=621-697.
DR   PDB; 6VI3; EM; 3.30 A; E/F=621-697.
DR   PDB; 6XLI; X-ray; 2.00 A; E/F/P=527-539.
DR   PDB; 7EYC; X-ray; 2.49 A; P/Q=594-601.
DR   PDB; 7KQK; X-ray; 2.60 A; C/P=541-550.
DR   PDB; 7MKF; EM; 3.00 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7MKG; EM; 3.07 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7MKH; EM; 3.30 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7NRQ; EM; 2.76 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7NRS; EM; 2.68 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7NRT; EM; 2.68 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7NRV; EM; 3.00 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7NRX; EM; 3.55 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7P65; EM; 2.70 A; A/B/C/D/E=1-758.
DR   PDB; 7P66; EM; 3.00 A; A/B/C/D/E=1-758.
DR   PDB; 7P67; EM; 3.10 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7P68; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7P6A; EM; 1.90 A; A/B/C/D/E=1-758.
DR   PDB; 7P6B; EM; 2.20 A; A/B/C/D/E=1-758.
DR   PDB; 7P6C; EM; 2.50 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7P6D; EM; 3.30 A; A/B/C/D/E=1-758.
DR   PDB; 7P6E; EM; 3.40 A; A/B/C/D/E/F/I/J/Q/R=1-758.
DR   PDB; 7PQC; EM; 4.10 A; O=519-712.
DR   PDB; 7PQP; EM; 4.10 A; O=519-712.
DR   PDB; 7QJV; EM; 3.29 A; A/B/C/D/E/F/G/H/I/J/K/L=1-758.
DR   PDB; 7QJW; EM; 2.81 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QJX; EM; 2.99 A; A/B/C/D/E/F/G/H/I/J/K/L=1-758.
DR   PDB; 7QJY; EM; 3.14 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QJZ; EM; 3.40 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QK1; EM; 3.03 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QK2; EM; 2.61 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QK3; EM; 2.44 A; A/B/C=1-758.
DR   PDB; 7QK5; EM; 1.92 A; A/B/C/D/E/F/G/H/K=1-758.
DR   PDB; 7QK6; EM; 2.27 A; A/B/C=1-758.
DR   PDB; 7QKF; EM; 2.83 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKG; EM; 3.36 A; A/B/C=1-758.
DR   PDB; 7QKH; EM; 3.17 A; A/B/C/D/E/G=1-758.
DR   PDB; 7QKI; EM; 3.13 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKJ; EM; 3.26 A; A/B/C/D/E/F/G/H/I/J/K/L=1-758.
DR   PDB; 7QKK; EM; 2.80 A; A/B/C=1-758.
DR   PDB; 7QKL; EM; 2.07 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKM; EM; 2.66 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKU; EM; 2.57 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKV; EM; 3.23 A; A/B/C/D/E/F/G/H/I=1-758.
DR   PDB; 7QKW; EM; 2.32 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKX; EM; 3.16 A; A/B/C/D/E/G=1-758.
DR   PDB; 7QKY; EM; 1.86 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QKZ; EM; 2.65 A; A/B/C/D/E/F/G/H/I=1-758.
DR   PDB; 7QL0; EM; 3.13 A; A/B/C/D/E/c=1-758.
DR   PDB; 7QL1; EM; 3.34 A; A/C/D=1-758.
DR   PDB; 7QL2; EM; 2.95 A; A/B/C=1-758.
DR   PDB; 7QL3; EM; 3.32 A; A/B/C/D/E/F=1-758.
DR   PDB; 7QL4; EM; 3.20 A; A/B/C/D/E/F=1-758.
DR   PDB; 7R4T; EM; 2.75 A; A/B/C/D/E/F=1-758.
DR   PDB; 7R5H; EM; 2.59 A; A/B/C/D/E/F=1-758.
DR   PDB; 7SP1; EM; 3.40 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O=1-758.
DR   PDB; 7U0Z; EM; 4.20 A; A/B/C=589-698.
DR   PDB; 7UPE; EM; 3.40 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7UPF; EM; 3.30 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7UPG; EM; 3.80 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 7YMN; EM; 3.46 A; A/B/C/D/E/F=614-708.
DR   PDB; 7YPG; EM; 2.50 A; A/B/C/D/E/F=614-708.
DR   PDB; 8AZU; EM; 3.10 A; C=1-758.
DR   PDB; 8BGS; EM; 3.16 A; A/B/C/D/E/F/r=1-758.
DR   PDB; 8BGV; EM; 3.27 A; A/B/C/D/E/F/n=1-758.
DR   PDB; 8BYN; EM; 2.60 A; A/B/C/D/E/F=1-758.
DR   PDB; 8CAQ; EM; 2.30 A; A/B/C/D/E=1-758.
DR   PDB; 8CAX; EM; 3.70 A; A/B/C/D/E/F=1-758.
DR   PDB; 8FNZ; EM; 3.88 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/a/b/c/d/e/f=580-597.
DR   PDB; 8FUG; EM; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W=623-695.
DR   PDB; 8FYU; X-ray; 1.85 A; C/E=729-738.
DR   PDB; 8G54; NMR; -; A/B/C/D/E=515-716.
DR   PDB; 8G55; NMR; -; A/B/C/D/E/F/G/H/I/J=515-716.
DR   PDB; 8G58; NMR; -; A/B/C/D/E/F/G/H/I/J=614-708.
DR   PDB; 8GCK; X-ray; 1.37 A; C/E=733-738.
DR   PDB; 8KDX; X-ray; 1.01 A; B=524-538.
DR   PDB; 8OH2; EM; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d=666-680.
DR   PDB; 8OHI; EM; 2.80 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R=667-679.
DR   PDB; 8OHP; EM; 2.70 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=667-679.
DR   PDB; 8OI0; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=667-679.
DR   PDB; 8OP0; X-ray; 1.54 A; B=618-629.
DR   PDB; 8OPI; X-ray; 1.83 A; B=618-629.
DR   PDB; 8ORE; EM; 2.50 A; A/B/C=404-758.
DR   PDB; 8ORF; EM; 2.50 A; A/B/C=404-758.
DR   PDB; 8ORG; EM; 2.30 A; A/B/C=404-758.
DR   PDB; 8OT6; EM; 2.00 A; A/B/C/D/E=1-758.
DR   PDB; 8OT9; EM; 3.40 A; A/B/C/D/E/F=1-758.
DR   PDB; 8OTC; EM; 3.20 A; A/B/C/D/E/F=1-758.
DR   PDB; 8OTG; EM; 2.10 A; A/B/C/D/E=1-758.
DR   PDB; 8OTH; EM; 3.40 A; A/B/C/D/E=1-758.
DR   PDB; 8OTI; EM; 2.70 A; A/B/C/D/E/F=1-758.
DR   PDB; 8OTJ; EM; 3.30 A; A/B/C/D/E/F/G=1-758.
DR   PDB; 8P34; EM; 2.61 A; A=602-695.
DR   PDB; 8PII; X-ray; 2.35 A; B=618-631.
DR   PDB; 8PPO; EM; 2.00 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=1-758.
DR   PDB; 8Q27; EM; 2.02 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q2J; EM; 2.23 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q2K; EM; 2.88 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q2L; EM; 2.20 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q7F; EM; 3.72 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q7L; EM; 2.82 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q7M; EM; 3.26 A; A/B/C/D/E/F/G/H/I=427-758.
DR   PDB; 8Q7P; EM; 3.28 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q7T; EM; 3.00 A; A/B/C/D/E/F/G/H/I=427-758.
DR   PDB; 8Q88; EM; 2.95 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8C; EM; 1.92 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8D; EM; 3.04 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8E; EM; 3.81 A; A/B/C/D/E/F/G/H/I/J/K/L=427-758.
DR   PDB; 8Q8F; EM; 2.93 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8L; EM; 3.04 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8M; EM; 2.95 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8R; EM; 2.10 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8S; EM; 2.68 A; A/B/C/D/E/F/G/H/I=427-758.
DR   PDB; 8Q8U; EM; 3.30 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8V; EM; 3.80 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8W; EM; 2.85 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8X; EM; 2.54 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8Y; EM; 2.88 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q8Z; EM; 3.16 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q92; EM; 3.05 A; A/B/C=588-681.
DR   PDB; 8Q97; EM; 2.99 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q98; EM; 1.75 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q99; EM; 2.70 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9A; EM; 3.04 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9B; EM; 3.10 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9C; EM; 3.40 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9D; EM; 3.16 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9E; EM; 2.97 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9F; EM; 1.91 A; A/B/C/D/E/c=427-758.
DR   PDB; 8Q9G; EM; 2.65 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9H; EM; 2.18 A; A/B/C/D/E/G=427-758.
DR   PDB; 8Q9I; EM; 2.56 A; A/C/E=427-758.
DR   PDB; 8Q9J; EM; 2.96 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9K; EM; 3.20 A; A/B/C/D/E/F=427-758.
DR   PDB; 8Q9L; EM; 2.76 A; A/B/C/D/E/F/G/H/I=427-758.
DR   PDB; 8Q9M; EM; 2.65 A; A/B/C/D/E/G=427-758.
DR   PDB; 8Q9O; EM; 3.10 A; A/B/C/D/E/G=427-758.
DR   PDB; 8QCP; EM; 3.21 A; A/B/C/D/E/F=427-758.
DR   PDB; 8QCR; EM; 2.75 A; A/C/E=427-758.
DR   PDB; 8QDV; X-ray; 2.50 A; C/F=527-539, C/F=635-648.
DR   PDB; 8QJJ; EM; 3.35 A; A/B/C/D/E/F=427-758.
DR   PDB; 8R3T; EM; 3.10 A; A/B/C/D/E/F=1-758.
DR   PDB; 8SEH; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 8SEI; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 8TTL; EM; 2.60 A; A/B/C/D/E/F=427-758.
DR   PDB; 8TTN; EM; 2.40 A; A/B/C/D/E=427-758.
DR   PDB; 8UQ7; EM; 2.31 A; A/B/C/D/E/F=622-696.
DR   PDB; 8V1N; EM; 3.00 A; A/B/C/D/E/F/G/H/I/J/K/L=612-630.
DR   PDB; 8WCP; EM; 3.28 A; A/B/C=427-758.
DR   PDB; 8ZWL; EM; 3.40 A; A/B/C/D/E/F=1-758.
DR   PDB; 8ZWM; EM; 3.20 A; A/B/C/D/E/F=1-758.
DR   PDB; 8ZX6; EM; 3.50 A; A/B/C/D/E/F=1-758.
DR   PDB; 9BBL; EM; 2.50 A; A/B/C/D/E/F/G/H/I=1-758.
DR   PDB; 9BBM; EM; 3.20 A; A/B/C/D/E/F=1-758.
DR   PDB; 9BXI; EM; 2.70 A; A/B/C/D/E/F=621-697.
DR   PDB; 9BXO; EM; 3.00 A; A/B/C/D/E/F=621-697.
DR   PDB; 9BXQ; EM; 3.10 A; C/D/E/F/G/H=621-697.
DR   PDB; 9BXR; EM; 3.20 A; C/D/E/F/G/H=621-697.
DR   PDB; 9CGX; EM; 2.97 A; A/B/C/D/E/F=427-758.
DR   PDB; 9CGZ; EM; 2.69 A; A/B/C/D/E/F=427-758.
DR   PDB; 9CZI; EM; 3.00 A; A/B/C/D/E/F/G/H/I/J=623-695.
DR   PDB; 9CZL; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=622-695.
DR   PDB; 9EO7; EM; 2.80 A; A=1-758.
DR   PDB; 9EO9; EM; 3.30 A; A/B=1-758.
DR   PDB; 9EOE; EM; 2.30 A; A=1-758.
DR   PDB; 9EOG; EM; 3.00 A; A/B/C/D/E/F=1-758.
DR   PDB; 9EOH; EM; 2.80 A; A/B/C/D/E/F=1-758.
DR   PDB; 9ERM; EM; 2.30 A; A/B/C/D/E=1-758.
DR   PDB; 9ERN; EM; 2.50 A; A/B/C/D/E/F=1-758.
DR   PDB; 9ERO; EM; 2.90 A; A/B/C/D/E/F/G/H/I/J=1-758.
DR   PDB; 9G13; X-ray; 1.80 A; B/D/F/H=686-698.
DR   PDB; 9GG0; EM; 2.81 A; A/B/C=588-694.
DR   PDB; 9GG1; EM; 2.26 A; A/B/C/D=590-696.
DR   PDB; 9GG6; EM; 3.36 A; A/B/C=586-681.
DR   PDB; 9H5G; EM; 2.48 A; A/B/C/D/E/F=427-758.
DR   PDB; 9H5J; EM; 2.72 A; A/B/C/D/E/F=427-758.
DR   PDB; 9HBB; EM; 3.00 A; A/B/C/D/E/F=608-708.
DR   PDBsum; 1I8H; -.
DR   PDBsum; 2MZ7; -.
DR   PDBsum; 2ON9; -.
DR   PDBsum; 3OVL; -.
DR   PDBsum; 4E0M; -.
DR   PDBsum; 4E0N; -.
DR   PDBsum; 4E0O; -.
DR   PDBsum; 4FL5; -.
DR   PDBsum; 4GLR; -.
DR   PDBsum; 4NP8; -.
DR   PDBsum; 4TQE; -.
DR   PDBsum; 4Y32; -.
DR   PDBsum; 4Y3B; -.
DR   PDBsum; 4Y5I; -.
DR   PDBsum; 5DMG; -.
DR   PDBsum; 5E2V; -.
DR   PDBsum; 5E2W; -.
DR   PDBsum; 5HF3; -.
DR   PDBsum; 5K7N; -.
DR   PDBsum; 5MO3; -.
DR   PDBsum; 5MP1; -.
DR   PDBsum; 5MP3; -.
DR   PDBsum; 5MP5; -.
DR   PDBsum; 5N5A; -.
DR   PDBsum; 5N5B; -.
DR   PDBsum; 5NVB; -.
DR   PDBsum; 5O3L; -.
DR   PDBsum; 5O3O; -.
DR   PDBsum; 5O3T; -.
DR   PDBsum; 5V5B; -.
DR   PDBsum; 5V5C; -.
DR   PDBsum; 5ZIA; -.
DR   PDBsum; 5ZV3; -.
DR   PDBsum; 6BB4; -.
DR   PDBsum; 6CVJ; -.
DR   PDBsum; 6CVN; -.
DR   PDBsum; 6DC8; -.
DR   PDBsum; 6DC9; -.
DR   PDBsum; 6DCA; -.
DR   PDBsum; 6FBW; -.
DR   PDBsum; 6FI5; -.
DR   PDBsum; 6GK7; -.
DR   PDBsum; 6GK8; -.
DR   PDBsum; 6GX5; -.
DR   PDBsum; 6H06; -.
DR   PDBsum; 6HRE; -.
DR   PDBsum; 6HRF; -.
DR   PDBsum; 6LRA; -.
DR   PDBsum; 6N4P; -.
DR   PDBsum; 6NK4; -.
DR   PDBsum; 6NWP; -.
DR   PDBsum; 6NWQ; -.
DR   PDBsum; 6ODG; -.
DR   PDBsum; 6PXR; -.
DR   PDBsum; 6QJH; -.
DR   PDBsum; 6QJM; -.
DR   PDBsum; 6QJP; -.
DR   PDBsum; 6QJQ; -.
DR   PDBsum; 6TJO; -.
DR   PDBsum; 6TJX; -.
DR   PDBsum; 6VH7; -.
DR   PDBsum; 6VHA; -.
DR   PDBsum; 6VHL; -.
DR   PDBsum; 6VI3; -.
DR   PDBsum; 6XLI; -.
DR   PDBsum; 7EYC; -.
DR   PDBsum; 7KQK; -.
DR   PDBsum; 7MKF; -.
DR   PDBsum; 7MKG; -.
DR   PDBsum; 7MKH; -.
DR   PDBsum; 7NRQ; -.
DR   PDBsum; 7NRS; -.
DR   PDBsum; 7NRT; -.
DR   PDBsum; 7NRV; -.
DR   PDBsum; 7NRX; -.
DR   PDBsum; 7P65; -.
DR   PDBsum; 7P66; -.
DR   PDBsum; 7P67; -.
DR   PDBsum; 7P68; -.
DR   PDBsum; 7P6A; -.
DR   PDBsum; 7P6B; -.
DR   PDBsum; 7P6C; -.
DR   PDBsum; 7P6D; -.
DR   PDBsum; 7P6E; -.
DR   PDBsum; 7PQC; -.
DR   PDBsum; 7PQP; -.
DR   PDBsum; 7QJV; -.
DR   PDBsum; 7QJW; -.
DR   PDBsum; 7QJX; -.
DR   PDBsum; 7QJY; -.
DR   PDBsum; 7QJZ; -.
DR   PDBsum; 7QK1; -.
DR   PDBsum; 7QK2; -.
DR   PDBsum; 7QK3; -.
DR   PDBsum; 7QK5; -.
DR   PDBsum; 7QK6; -.
DR   PDBsum; 7QKF; -.
DR   PDBsum; 7QKG; -.
DR   PDBsum; 7QKH; -.
DR   PDBsum; 7QKI; -.
DR   PDBsum; 7QKJ; -.
DR   PDBsum; 7QKK; -.
DR   PDBsum; 7QKL; -.
DR   PDBsum; 7QKM; -.
DR   PDBsum; 7QKU; -.
DR   PDBsum; 7QKV; -.
DR   PDBsum; 7QKW; -.
DR   PDBsum; 7QKX; -.
DR   PDBsum; 7QKY; -.
DR   PDBsum; 7QKZ; -.
DR   PDBsum; 7QL0; -.
DR   PDBsum; 7QL1; -.
DR   PDBsum; 7QL2; -.
DR   PDBsum; 7QL3; -.
DR   PDBsum; 7QL4; -.
DR   PDBsum; 7R4T; -.
DR   PDBsum; 7R5H; -.
DR   PDBsum; 7SP1; -.
DR   PDBsum; 7U0Z; -.
DR   PDBsum; 7UPE; -.
DR   PDBsum; 7UPF; -.
DR   PDBsum; 7UPG; -.
DR   PDBsum; 7YMN; -.
DR   PDBsum; 7YPG; -.
DR   PDBsum; 8AZU; -.
DR   PDBsum; 8BGS; -.
DR   PDBsum; 8BGV; -.
DR   PDBsum; 8BYN; -.
DR   PDBsum; 8CAQ; -.
DR   PDBsum; 8CAX; -.
DR   PDBsum; 8FNZ; -.
DR   PDBsum; 8FUG; -.
DR   PDBsum; 8FYU; -.
DR   PDBsum; 8G54; -.
DR   PDBsum; 8G55; -.
DR   PDBsum; 8G58; -.
DR   PDBsum; 8GCK; -.
DR   PDBsum; 8KDX; -.
DR   PDBsum; 8OH2; -.
DR   PDBsum; 8OHI; -.
DR   PDBsum; 8OHP; -.
DR   PDBsum; 8OI0; -.
DR   PDBsum; 8OP0; -.
DR   PDBsum; 8OPI; -.
DR   PDBsum; 8ORE; -.
DR   PDBsum; 8ORF; -.
DR   PDBsum; 8ORG; -.
DR   PDBsum; 8OT6; -.
DR   PDBsum; 8OT9; -.
DR   PDBsum; 8OTC; -.
DR   PDBsum; 8OTG; -.
DR   PDBsum; 8OTH; -.
DR   PDBsum; 8OTI; -.
DR   PDBsum; 8OTJ; -.
DR   PDBsum; 8P34; -.
DR   PDBsum; 8PII; -.
DR   PDBsum; 8PPO; -.
DR   PDBsum; 8Q27; -.
DR   PDBsum; 8Q2J; -.
DR   PDBsum; 8Q2K; -.
DR   PDBsum; 8Q2L; -.
DR   PDBsum; 8Q7F; -.
DR   PDBsum; 8Q7L; -.
DR   PDBsum; 8Q7M; -.
DR   PDBsum; 8Q7P; -.
DR   PDBsum; 8Q7T; -.
DR   PDBsum; 8Q88; -.
DR   PDBsum; 8Q8C; -.
DR   PDBsum; 8Q8D; -.
DR   PDBsum; 8Q8E; -.
DR   PDBsum; 8Q8F; -.
DR   PDBsum; 8Q8L; -.
DR   PDBsum; 8Q8M; -.
DR   PDBsum; 8Q8R; -.
DR   PDBsum; 8Q8S; -.
DR   PDBsum; 8Q8U; -.
DR   PDBsum; 8Q8V; -.
DR   PDBsum; 8Q8W; -.
DR   PDBsum; 8Q8X; -.
DR   PDBsum; 8Q8Y; -.
DR   PDBsum; 8Q8Z; -.
DR   PDBsum; 8Q92; -.
DR   PDBsum; 8Q97; -.
DR   PDBsum; 8Q98; -.
DR   PDBsum; 8Q99; -.
DR   PDBsum; 8Q9A; -.
DR   PDBsum; 8Q9B; -.
DR   PDBsum; 8Q9C; -.
DR   PDBsum; 8Q9D; -.
DR   PDBsum; 8Q9E; -.
DR   PDBsum; 8Q9F; -.
DR   PDBsum; 8Q9G; -.
DR   PDBsum; 8Q9H; -.
DR   PDBsum; 8Q9I; -.
DR   PDBsum; 8Q9J; -.
DR   PDBsum; 8Q9K; -.
DR   PDBsum; 8Q9L; -.
DR   PDBsum; 8Q9M; -.
DR   PDBsum; 8Q9O; -.
DR   PDBsum; 8QCP; -.
DR   PDBsum; 8QCR; -.
DR   PDBsum; 8QDV; -.
DR   PDBsum; 8QJJ; -.
DR   PDBsum; 8R3T; -.
DR   PDBsum; 8SEH; -.
DR   PDBsum; 8SEI; -.
DR   PDBsum; 8TTL; -.
DR   PDBsum; 8TTN; -.
DR   PDBsum; 8UQ7; -.
DR   PDBsum; 8V1N; -.
DR   PDBsum; 8WCP; -.
DR   PDBsum; 8ZWL; -.
DR   PDBsum; 8ZWM; -.
DR   PDBsum; 8ZX6; -.
DR   PDBsum; 9BBL; -.
DR   PDBsum; 9BBM; -.
DR   PDBsum; 9BXI; -.
DR   PDBsum; 9BXO; -.
DR   PDBsum; 9BXQ; -.
DR   PDBsum; 9BXR; -.
DR   PDBsum; 9CGX; -.
DR   PDBsum; 9CGZ; -.
DR   PDBsum; 9CZI; -.
DR   PDBsum; 9CZL; -.
DR   PDBsum; 9EO7; -.
DR   PDBsum; 9EO9; -.
DR   PDBsum; 9EOE; -.
DR   PDBsum; 9EOG; -.
DR   PDBsum; 9EOH; -.
DR   PDBsum; 9ERM; -.
DR   PDBsum; 9ERN; -.
DR   PDBsum; 9ERO; -.
DR   PDBsum; 9G13; -.
DR   PDBsum; 9GG0; -.
DR   PDBsum; 9GG1; -.
DR   PDBsum; 9GG6; -.
DR   PDBsum; 9H5G; -.
DR   PDBsum; 9H5J; -.
DR   PDBsum; 9HBB; -.
DR   AlphaFoldDB; P10636; -.
DR   BMRB; P10636; -.
DR   EMDB; EMD-0077; -.
DR   EMDB; EMD-0259; -.
DR   EMDB; EMD-0260; -.
DR   EMDB; EMD-0527; -.
DR   EMDB; EMD-0528; -.
DR   EMDB; EMD-10512; -.
DR   EMDB; EMD-10514; -.
DR   EMDB; EMD-12549; -.
DR   EMDB; EMD-12550; -.
DR   EMDB; EMD-12551; -.
DR   EMDB; EMD-12552; -.
DR   EMDB; EMD-12553; -.
DR   EMDB; EMD-13218; -.
DR   EMDB; EMD-13219; -.
DR   EMDB; EMD-13220; -.
DR   EMDB; EMD-13221; -.
DR   EMDB; EMD-13223; -.
DR   EMDB; EMD-13224; -.
DR   EMDB; EMD-13225; -.
DR   EMDB; EMD-13226; -.
DR   EMDB; EMD-13227; -.
DR   EMDB; EMD-14023; -.
DR   EMDB; EMD-14024; -.
DR   EMDB; EMD-14025; -.
DR   EMDB; EMD-14026; -.
DR   EMDB; EMD-14027; -.
DR   EMDB; EMD-14028; -.
DR   EMDB; EMD-14029; -.
DR   EMDB; EMD-14030; -.
DR   EMDB; EMD-14038; -.
DR   EMDB; EMD-14039; -.
DR   EMDB; EMD-14040; -.
DR   EMDB; EMD-14041; -.
DR   EMDB; EMD-14042; -.
DR   EMDB; EMD-14043; -.
DR   EMDB; EMD-14044; -.
DR   EMDB; EMD-14045; -.
DR   EMDB; EMD-14046; -.
DR   EMDB; EMD-14047; -.
DR   EMDB; EMD-14053; -.
DR   EMDB; EMD-14054; -.
DR   EMDB; EMD-14055; -.
DR   EMDB; EMD-14056; -.
DR   EMDB; EMD-14057; -.
DR   EMDB; EMD-14058; -.
DR   EMDB; EMD-14059; -.
DR   EMDB; EMD-14060; -.
DR   EMDB; EMD-14061; -.
DR   EMDB; EMD-14062; -.
DR   EMDB; EMD-14063; -.
DR   EMDB; EMD-14316; -.
DR   EMDB; EMD-14320; -.
DR   EMDB; EMD-15772; -.
DR   EMDB; EMD-16035; -.
DR   EMDB; EMD-16039; -.
DR   EMDB; EMD-16329; -.
DR   EMDB; EMD-16532; -.
DR   EMDB; EMD-16535; -.
DR   EMDB; EMD-16876; -.
DR   EMDB; EMD-16881; -.
DR   EMDB; EMD-16883; -.
DR   EMDB; EMD-16886; -.
DR   EMDB; EMD-17121; -.
DR   EMDB; EMD-17122; -.
DR   EMDB; EMD-17123; -.
DR   EMDB; EMD-17171; -.
DR   EMDB; EMD-17173; -.
DR   EMDB; EMD-17174; -.
DR   EMDB; EMD-17178; -.
DR   EMDB; EMD-17179; -.
DR   EMDB; EMD-17180; -.
DR   EMDB; EMD-17181; -.
DR   EMDB; EMD-17383; -.
DR   EMDB; EMD-17806; -.
DR   EMDB; EMD-18070; -.
DR   EMDB; EMD-18109; -.
DR   EMDB; EMD-18111; -.
DR   EMDB; EMD-18112; -.
DR   EMDB; EMD-18215; -.
DR   EMDB; EMD-18219; -.
DR   EMDB; EMD-18224; -.
DR   EMDB; EMD-18228; -.
DR   EMDB; EMD-18233; -.
DR   EMDB; EMD-18249; -.
DR   EMDB; EMD-18250; -.
DR   EMDB; EMD-18251; -.
DR   EMDB; EMD-18252; -.
DR   EMDB; EMD-18253; -.
DR   EMDB; EMD-18254; -.
DR   EMDB; EMD-18255; -.
DR   EMDB; EMD-18258; -.
DR   EMDB; EMD-18259; -.
DR   EMDB; EMD-18261; -.
DR   EMDB; EMD-18262; -.
DR   EMDB; EMD-18263; -.
DR   EMDB; EMD-18264; -.
DR   EMDB; EMD-18265; -.
DR   EMDB; EMD-18266; -.
DR   EMDB; EMD-18268; -.
DR   EMDB; EMD-18270; -.
DR   EMDB; EMD-18271; -.
DR   EMDB; EMD-18272; -.
DR   EMDB; EMD-18273; -.
DR   EMDB; EMD-18275; -.
DR   EMDB; EMD-18276; -.
DR   EMDB; EMD-18277; -.
DR   EMDB; EMD-18278; -.
DR   EMDB; EMD-18279; -.
DR   EMDB; EMD-18280; -.
DR   EMDB; EMD-18281; -.
DR   EMDB; EMD-18282; -.
DR   EMDB; EMD-18283; -.
DR   EMDB; EMD-18284; -.
DR   EMDB; EMD-18285; -.
DR   EMDB; EMD-18286; -.
DR   EMDB; EMD-18287; -.
DR   EMDB; EMD-18331; -.
DR   EMDB; EMD-18333; -.
DR   EMDB; EMD-18448; -.
DR   EMDB; EMD-18874; -.
DR   EMDB; EMD-18990; -.
DR   EMDB; EMD-19846; -.
DR   EMDB; EMD-19849; -.
DR   EMDB; EMD-19852; -.
DR   EMDB; EMD-19854; -.
DR   EMDB; EMD-19855; -.
DR   EMDB; EMD-19926; -.
DR   EMDB; EMD-19927; -.
DR   EMDB; EMD-19928; -.
DR   EMDB; EMD-21200; -.
DR   EMDB; EMD-21201; -.
DR   EMDB; EMD-21207; -.
DR   EMDB; EMD-26268; -.
DR   EMDB; EMD-29458; -.
DR   EMDB; EMD-33934; -.
DR   EMDB; EMD-33999; -.
DR   EMDB; EMD-35403; -.
DR   EMDB; EMD-35404; -.
DR   EMDB; EMD-35405; -.
DR   EMDB; EMD-35406; -.
DR   EMDB; EMD-35407; -.
DR   EMDB; EMD-35408; -.
DR   EMDB; EMD-35409; -.
DR   EMDB; EMD-3741; -.
DR   EMDB; EMD-3742; -.
DR   EMDB; EMD-3743; -.
DR   EMDB; EMD-3744; -.
DR   EMDB; EMD-40411; -.
DR   EMDB; EMD-40413; -.
DR   EMDB; EMD-41610; -.
DR   EMDB; EMD-41611; -.
DR   EMDB; EMD-42463; -.
DR   EMDB; EMD-42886; -.
DR   EMDB; EMD-44421; -.
DR   EMDB; EMD-44422; -.
DR   EMDB; EMD-45005; -.
DR   EMDB; EMD-45007; -.
DR   EMDB; EMD-45008; -.
DR   EMDB; EMD-45009; -.
DR   EMDB; EMD-45588; -.
DR   EMDB; EMD-45589; -.
DR   EMDB; EMD-4563; -.
DR   EMDB; EMD-4565; -.
DR   EMDB; EMD-4566; -.
DR   EMDB; EMD-46417; -.
DR   EMDB; EMD-46420; -.
DR   EMDB; EMD-50148; -.
DR   EMDB; EMD-50152; -.
DR   EMDB; EMD-50153; -.
DR   EMDB; EMD-50155; -.
DR   EMDB; EMD-50156; -.
DR   EMDB; EMD-50157; -.
DR   EMDB; EMD-50159; -.
DR   EMDB; EMD-50160; -.
DR   EMDB; EMD-50161; -.
DR   EMDB; EMD-50162; -.
DR   EMDB; EMD-51319; -.
DR   EMDB; EMD-51320; -.
DR   EMDB; EMD-51325; -.
DR   EMDB; EMD-51884; -.
DR   EMDB; EMD-51886; -.
DR   EMDB; EMD-52014; -.
DR   EMDB; EMD-60531; -.
DR   EMDB; EMD-60532; -.
DR   EMDB; EMD-60533; -.
DR   EMDB; EMD-60539; -.
DR   EMDB; EMD-7520; -.
DR   EMDB; EMD-7522; -.
DR   EMDB; EMD-7523; -.
DR   EMDB; EMD-7769; -.
DR   EMDB; EMD-7771; -.
DR   EMDB; EMD-8634; -.
DR   EMDB; EMD-8635; -.
DR   SASBDB; P10636; -.
DR   SMR; P10636; -.
DR   BioGRID; 110308; 1103.
DR   CORUM; P10636; -.
DR   DIP; DIP-29753N; -.
DR   ELM; P10636; -.
DR   IntAct; P10636; 2079.
DR   MINT; P10636; -.
DR   STRING; 9606.ENSP00000340820; -.
DR   BindingDB; P10636; -.
DR   ChEMBL; CHEMBL1293224; -.
DR   DrugBank; DB00637; Astemizole.
DR   DrugBank; DB01248; Docetaxel.
DR   DrugBank; DB14914; Flortaucipir F-18.
DR   DrugBank; DB00448; Lansoprazole.
DR   DrugBank; DB01229; Paclitaxel.
DR   DrugCentral; P10636; -.
DR   GlyConnect; 2885; 1 O-GlcNAc glycan (6 sites).
DR   GlyCosmos; P10636; 34 sites, 1 glycan.
DR   GlyGen; P10636; 8 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (6 sites).
DR   iPTMnet; P10636; -.
DR   MetOSite; P10636; -.
DR   PhosphoSitePlus; P10636; -.
DR   BioMuta; MAPT; -.
DR   DMDM; 334302961; -.
DR   jPOST; P10636; -.
DR   MassIVE; P10636; -.
DR   PaxDb; 9606-ENSP00000340820; -.
DR   PeptideAtlas; P10636; -.
DR   ProteomicsDB; 52624; -. [P10636-1]
DR   ProteomicsDB; 52625; -. [P10636-2]
DR   ProteomicsDB; 52626; -. [P10636-3]
DR   ProteomicsDB; 52627; -. [P10636-4]
DR   ProteomicsDB; 52628; -. [P10636-5]
DR   ProteomicsDB; 52629; -. [P10636-6]
DR   ProteomicsDB; 52630; -. [P10636-7]
DR   ProteomicsDB; 52631; -. [P10636-8]
DR   ProteomicsDB; 52632; -. [P10636-9]
DR   Pumba; P10636; -.
DR   TopDownProteomics; P10636-3; -. [P10636-3]
DR   ABCD; P10636; 90 sequenced antibodies.
DR   Antibodypedia; 3124; 7399 antibodies from 54 providers.
DR   DNASU; 4137; -.
DR   Ensembl; ENST00000334239.12; ENSP00000334886.8; ENSG00000186868.18. [P10636-2]
DR   Ensembl; ENST00000351559.10; ENSP00000303214.7; ENSG00000186868.18. [P10636-8]
DR   Ensembl; ENST00000415613.6; ENSP00000410838.2; ENSG00000186868.18. [P10636-9]
DR   Ensembl; ENST00000420682.7; ENSP00000413056.2; ENSG00000186868.18. [P10636-7]
DR   Ensembl; ENST00000431008.7; ENSP00000389250.3; ENSG00000186868.18. [P10636-5]
DR   Ensembl; ENST00000446361.7; ENSP00000408975.3; ENSG00000186868.18. [P10636-6]
DR   Ensembl; ENST00000535772.6; ENSP00000443028.2; ENSG00000186868.18. [P10636-4]
DR   Ensembl; ENST00000571987.5; ENSP00000458742.1; ENSG00000186868.18. [P10636-1]
DR   Ensembl; ENST00000574436.5; ENSP00000460965.1; ENSG00000186868.18. [P10636-8]
DR   Ensembl; ENST00000612872.4; ENSP00000478602.1; ENSG00000277956.4. [P10636-7]
DR   Ensembl; ENST00000613360.4; ENSP00000483784.1; ENSG00000276155.4. [P10636-7]
DR   Ensembl; ENST00000620070.4; ENSP00000484491.1; ENSG00000277956.4. [P10636-8]
DR   Ensembl; ENST00000620818.4; ENSP00000484321.1; ENSG00000277956.4. [P10636-5]
DR   Ensembl; ENST00000620981.4; ENSP00000481769.1; ENSG00000276155.4. [P10636-5]
DR   Ensembl; ENST00000621329.4; ENSP00000477703.1; ENSG00000276155.4. [P10636-8]
DR   Ensembl; ENST00000622106.2; ENSP00000482244.1; ENSG00000277956.4. [P10636-6]
DR   Ensembl; ENST00000622728.1; ENSP00000479142.1; ENSG00000276155.4. [P10636-6]
DR   Ensembl; ENST00000626571.2; ENSP00000486039.1; ENSG00000276155.4. [P10636-6]
DR   Ensembl; ENST00000628393.2; ENSP00000487570.1; ENSG00000276155.4. [P10636-2]
DR   Ensembl; ENST00000631447.1; ENSP00000488373.1; ENSG00000277956.4. [P10636-5]
DR   Ensembl; ENST00000632500.1; ENSP00000487837.1; ENSG00000277956.4. [P10636-7]
DR   Ensembl; ENST00000633047.1; ENSP00000488245.1; ENSG00000277956.4. [P10636-2]
DR   Ensembl; ENST00000634049.1; ENSP00000487819.1; ENSG00000277956.4. [P10636-8]
DR   Ensembl; ENST00000680542.1; ENSP00000505258.1; ENSG00000186868.18. [P10636-7]
DR   Ensembl; ENST00000703922.1; ENSP00000515557.1; ENSG00000186868.18. [P10636-7]
DR   Ensembl; ENST00000703923.1; ENSP00000515558.1; ENSG00000186868.18. [P10636-6]
DR   Ensembl; ENST00000703924.1; ENSP00000515559.1; ENSG00000186868.18. [P10636-7]
DR   Ensembl; ENST00000703978.1; ENSP00000515600.1; ENSG00000186868.18. [P10636-8]
DR   GeneID; 4137; -.
DR   KEGG; hsa:4137; -.
DR   UCSC; uc002ijr.5; human. [P10636-1]
DR   AGR; HGNC:6893; -.
DR   CTD; 4137; -.
DR   DisGeNET; 4137; -.
DR   GeneCards; MAPT; -.
DR   GeneReviews; MAPT; -.
DR   HGNC; HGNC:6893; MAPT.
DR   HPA; ENSG00000186868; Tissue enhanced (brain, skeletal muscle).
DR   MalaCards; MAPT; -.
DR   MIM; 157140; gene+phenotype.
DR   MIM; 172700; phenotype.
DR   MIM; 260540; phenotype.
DR   MIM; 600274; phenotype.
DR   MIM; 601104; phenotype.
DR   neXtProt; NX_P10636; -.
DR   NIAGADS; ENSG00000186868; -.
DR   OpenTargets; ENSG00000186868; -.
DR   Orphanet; 275864; Behavioral variant of frontotemporal dementia.
DR   Orphanet; 240071; Classic progressive supranuclear palsy syndrome.
DR   Orphanet; 100070; Progressive non-fluent aphasia.
DR   Orphanet; 240103; Progressive supranuclear palsy-corticobasal syndrome.
DR   Orphanet; 240085; Progressive supranuclear palsy-predominant parkinsonism syndrome.
DR   Orphanet; 240112; Progressive supranuclear palsy-progressive non-fluent aphasia syndrome.
DR   Orphanet; 240094; Progressive supranuclear palsy-pure akinesia with gait freezing syndrome.
DR   Orphanet; 100069; Semantic dementia.
DR   PharmGKB; PA238; -.
DR   VEuPathDB; HostDB:ENSG00000186868; -.
DR   eggNOG; KOG2418; Eukaryota.
DR   GeneTree; ENSGT00940000155494; -.
DR   HOGENOM; CLU_021741_2_0_1; -.
DR   InParanoid; P10636; -.
DR   OrthoDB; 9378527at2759; -.
DR   TreeFam; TF316358; -.
DR   PathwayCommons; P10636; -.
DR   Reactome; R-HSA-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; R-HSA-9619483; Activation of AMPK downstream of NMDARs. [P10636-8]
DR   Reactome; R-HSA-9833482; PKR-mediated signaling. [P10636-8]
DR   SABIO-RK; P10636; -.
DR   SignaLink; P10636; -.
DR   SIGNOR; P10636; -.
DR   BioGRID-ORCS; 4137; 23 hits in 1151 CRISPR screens.
DR   CD-CODE; 03D56D03; Tau inclusion.
DR   CD-CODE; 24B12ACB; Synthetic Condensate 000346.
DR   CD-CODE; 804901D1; Nuclear speckle.
DR   CD-CODE; 8188F968; Tau-Prion Multiphasic condensate.
DR   CD-CODE; 8C2F96ED; Centrosome.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; MAPT; human.
DR   EvolutionaryTrace; P10636; -.
DR   GeneWiki; Tau_protein; -.
DR   GenomeRNAi; 4137; -.
DR   Pharos; P10636; Tclin.
DR   PRO; PR:P10636; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P10636; protein.
DR   Bgee; ENSG00000186868; Expressed in cortical plate and 104 other cell types or tissues.
DR   ExpressionAtlas; P10636; baseline and differential.
DR   GO; GO:0030673; C:axolemma; IDA:CAFA.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:1904115; C:axon cytoplasm; IEA:GOC.
DR   GO; GO:0044297; C:cell body; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; TAS:ARUK-UCL.
DR   GO; GO:0005576; C:extracellular region; NAS:ARUK-UCL.
DR   GO; GO:0097386; C:glial cell projection; ISS:ARUK-UCL.
DR   GO; GO:0030426; C:growth cone; IDA:UniProtKB.
DR   GO; GO:0044304; C:main axon; ISS:ARUK-UCL.
DR   GO; GO:0045121; C:membrane raft; ISS:ARUK-UCL.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:CAFA.
DR   GO; GO:0005739; C:mitochondrion; TAS:ARUK-UCL.
DR   GO; GO:0097418; C:neurofibrillary tangle; IDA:CAFA.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0043025; C:neuronal cell body; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0034399; C:nuclear periphery; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0036477; C:somatodendritic compartment; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0045298; C:tubulin complex; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; TAS:ARUK-UCL.
DR   GO; GO:0034185; F:apolipoprotein binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0003690; F:double-stranded DNA binding; TAS:ARUK-UCL.
DR   GO; GO:0034452; F:dynactin binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0099077; F:histone-dependent DNA binding; TAS:ARUK-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; IPI:ARUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IDA:CAFA.
DR   GO; GO:0071813; F:lipoprotein particle binding; IPI:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IDA:UniProtKB.
DR   GO; GO:0099609; F:microtubule lateral binding; IMP:CAFA.
DR   GO; GO:0003680; F:minor groove of adenine-thymine-rich DNA binding; TAS:ARUK-UCL.
DR   GO; GO:0035091; F:phosphatidylinositol binding; TAS:ARUK-UCL.
DR   GO; GO:1902936; F:phosphatidylinositol bisphosphate binding; TAS:ARUK-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:ARUK-UCL.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; TAS:ARUK-UCL.
DR   GO; GO:0003723; F:RNA binding; TAS:ARUK-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; TAS:ARUK-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; TAS:ARUK-UCL.
DR   GO; GO:1990000; P:amyloid fibril formation; IDA:DisProt.
DR   GO; GO:0048143; P:astrocyte activation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0061564; P:axon development; TAS:ARUK-UCL.
DR   GO; GO:0098930; P:axonal transport; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0019896; P:axonal transport of mitochondrion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; NAS:ARUK-UCL.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; TAS:ARUK-UCL.
DR   GO; GO:0034605; P:cellular response to heat; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; TAS:ARUK-UCL.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; TAS:ARUK-UCL.
DR   GO; GO:0021954; P:central nervous system neuron development; TAS:ARUK-UCL.
DR   GO; GO:0031122; P:cytoplasmic microtubule organization; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006974; P:DNA damage response; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0048699; P:generation of neurons; NAS:UniProtKB.
DR   GO; GO:0048312; P:intracellular distribution of mitochondria; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0007611; P:learning or memory; IMP:ARUK-UCL.
DR   GO; GO:0007613; P:memory; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0001774; P:microglial cell activation; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0046785; P:microtubule polymerization; IDA:ARUK-UCL.
DR   GO; GO:1903748; P:negative regulation of establishment of protein localization to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0090258; P:negative regulation of mitochondrial fission; IMP:ARUK-UCL.
DR   GO; GO:0010917; P:negative regulation of mitochondrial membrane potential; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904428; P:negative regulation of tubulin deacetylation; IGI:ARUK-UCL.
DR   GO; GO:1902988; P:neurofibrillary tangle assembly; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0031175; P:neuron projection development; IBA:GO_Central.
DR   GO; GO:0072386; P:plus-end-directed organelle transport along microtubule; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0045773; P:positive regulation of axon extension; IDA:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IDA:UniProtKB.
DR   GO; GO:1903829; P:positive regulation of protein localization; IMP:CAFA.
DR   GO; GO:1902474; P:positive regulation of protein localization to synapse; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IMP:ARUK-UCL.
DR   GO; GO:0051260; P:protein homooligomerization; IPI:ARUK-UCL.
DR   GO; GO:0051258; P:protein polymerization; IMP:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; IGI:MGI.
DR   GO; GO:0050848; P:regulation of calcium-mediated signaling; IDA:ARUK-UCL.
DR   GO; GO:1900034; P:regulation of cellular response to heat; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0033044; P:regulation of chromosome organization; TAS:ARUK-UCL.
DR   GO; GO:1900452; P:regulation of long-term synaptic depression; TAS:ARUK-UCL.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IMP:CAFA.
DR   GO; GO:0031113; P:regulation of microtubule polymerization; TAS:ARUK-UCL.
DR   GO; GO:0031110; P:regulation of microtubule polymerization or depolymerization; IMP:CAFA.
DR   GO; GO:0090140; P:regulation of mitochondrial fission; IC:ParkinsonsUK-UCL.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; TAS:ARUK-UCL.
DR   GO; GO:0010288; P:response to lead ion; ISS:ARUK-UCL.
DR   GO; GO:0016072; P:rRNA metabolic process; TAS:ARUK-UCL.
DR   GO; GO:0034063; P:stress granule assembly; TAS:ARUK-UCL.
DR   GO; GO:0097435; P:supramolecular fiber organization; IDA:CAFA.
DR   GO; GO:0007416; P:synapse assembly; IMP:ARUK-UCL.
DR   GO; GO:0050808; P:synapse organization; IMP:ParkinsonsUK-UCL.
DR   DisProt; DP01100; -. [P10636-8]
DR   InterPro; IPR027324; MAP2/MAP4/Tau.
DR   InterPro; IPR001084; MAP_tubulin-bd_rpt.
DR   InterPro; IPR002955; Tau.
DR   PANTHER; PTHR11501; MICROTUBULE-ASSOCIATED PROTEIN; 1.
DR   PANTHER; PTHR11501:SF14; MICROTUBULE-ASSOCIATED PROTEIN TAU; 1.
DR   Pfam; PF00418; Tubulin-binding; 4.
DR   PRINTS; PR01261; TAUPROTEIN.
DR   PROSITE; PS00229; TAU_MAP_1; 4.
DR   PROSITE; PS51491; TAU_MAP_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Alzheimer disease;
KW   Cell membrane; Cell projection; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease variant; Disulfide bond; Glycation;
KW   Glycoprotein; Isopeptide bond; Membrane; Methylation; Microtubule;
KW   Neurodegeneration; Parkinsonism; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Repeat; Secreted; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:1512244"
FT   CHAIN           2..758
FT                   /note="Microtubule-associated protein tau"
FT                   /id="PRO_0000072739"
FT   REPEAT          561..591
FT                   /note="Tau/MAP 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00824,
FT                   ECO:0000305|PubMed:7706316"
FT   REPEAT          592..622
FT                   /note="Tau/MAP 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00824,
FT                   ECO:0000305|PubMed:7706316"
FT   REPEAT          623..653
FT                   /note="Tau/MAP 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00824,
FT                   ECO:0000305|PubMed:7706316"
FT   REPEAT          654..685
FT                   /note="Tau/MAP 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00824,
FT                   ECO:0000305|PubMed:7706316"
FT   REGION          1..573
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          561..685
FT                   /note="Microtubule-binding domain"
FT                   /evidence="ECO:0000269|PubMed:7706316"
FT   REGION          715..734
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1..26
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        61..71
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        179..189
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        207..216
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        217..228
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        314..323
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        324..340
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        344..356
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        381..393
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        442..453
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        455..466
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        491..503
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        504..531
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        718..733
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            24
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            44
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            67
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            381
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            391
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            392
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            394
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            465
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            497
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            507
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            541
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            557
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            571
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            574
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            584
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            591
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            607
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            611
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            615
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            628
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            634
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            638
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            648
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            657
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            660
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            687
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            692
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            700
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            702
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            712
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   SITE            755
FT                   /note="Not glycated"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:1512244"
FT   MOD_RES         18
FT                   /note="Phosphotyrosine; by FYN"
FT                   /evidence="ECO:0000269|PubMed:14999081"
FT   MOD_RES         29
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19332"
FT   MOD_RES         61
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P19332"
FT   MOD_RES         69
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         71
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P19332"
FT   MOD_RES         111
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         214
FT                   /note="Phosphoserine; by SGK1"
FT                   /evidence="ECO:0000269|PubMed:16982696"
FT   MOD_RES         396
FT                   /note="Phosphoserine; in PHF-tau"
FT                   /evidence="ECO:0000269|PubMed:1899488"
FT   MOD_RES         470
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:9614189"
FT   MOD_RES         472
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         480
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         480
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         484
FT                   /note="Deamidated asparagine; in tau and PHF-tau; partial"
FT                   /evidence="ECO:0000269|PubMed:1512244"
FT   MOD_RES         486
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         492
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         498
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:15546861"
FT   MOD_RES         502
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         508
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         512
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         514
FT                   /note="Phosphotyrosine; by TTBK1"
FT                   /evidence="ECO:0000269|PubMed:16923168"
FT   MOD_RES         515
FT                   /note="Phosphoserine; by PDPK1 and TTBK1"
FT                   /evidence="ECO:0000269|PubMed:16923168"
FT   MOD_RES         516
FT                   /note="Phosphoserine; by PDPK1 and TTBK1"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0000269|PubMed:16923168, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:9614189"
FT   MOD_RES         519
FT                   /note="Phosphoserine; by CK1, PDPK1 and TTBK1"
FT                   /evidence="ECO:0000269|PubMed:14761950,
FT                   ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16923168,
FT                   ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,
FT                   ECO:0000269|PubMed:9614189, ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         522
FT                   /note="Phosphothreonine; by CK1 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:14761950,
FT                   ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:19451179"
FT   MOD_RES         529
FT                   /note="Phosphothreonine; by BRSK1, BRSK2, DYRK2 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0000269|PubMed:18599021, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:9614189"
FT   MOD_RES         531
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:9614189"
FT   MOD_RES         534
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:16443603,
FT                   ECO:0000269|PubMed:19451179"
FT   MOD_RES         542
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         548
FT                   /note="Phosphothreonine; by GSK3-beta and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:14690523,
FT                   ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16443603,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         552
FT                   /note="Phosphoserine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:9614189,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         554
FT                   /note="Phosphoserine; by PHK"
FT                   /evidence="ECO:0000269|PubMed:16443603,
FT                   ECO:0000269|PubMed:8999860"
FT   MOD_RES         576
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         576
FT                   /note="N6-methyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         579
FT                   /note="Phosphoserine; by MARK1, MARK2, MARK3, MARK4, BRSK1,
FT                   BRSK2 and PHK"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0000269|PubMed:16443603, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:23666762,
FT                   ECO:0000269|PubMed:7706316, ECO:0000269|PubMed:8999860,
FT                   ECO:0000269|PubMed:9614189"
FT   MOD_RES         596
FT                   /note="Deamidated asparagine; in tau and PHF-tau; partial"
FT                   /evidence="ECO:0000269|PubMed:1512244"
FT   MOD_RES         598
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         602
FT                   /note="Phosphoserine; by PHK"
FT                   /evidence="ECO:0000269|PubMed:8999860"
FT   MOD_RES         607
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         610
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7706316"
FT   MOD_RES         615
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         622
FT                   /note="Phosphoserine; by PHK"
FT                   /evidence="ECO:0000269|PubMed:7706316,
FT                   ECO:0000269|PubMed:8999860"
FT   MOD_RES         628
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         628
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         634
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         638
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         641
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7706316"
FT   MOD_RES         648
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         660
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         664
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         666
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         669
FT                   /note="Phosphoserine; by PHK"
FT                   /evidence="ECO:0000269|PubMed:8999860"
FT   MOD_RES         673
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:7706316"
FT   MOD_RES         686
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         702
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         711
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         713
FT                   /note="Phosphoserine; by CK1 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:14761950,
FT                   ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:16443603,
FT                   ECO:0000269|PubMed:19451179, ECO:0000269|PubMed:21327254,
FT                   ECO:0000269|PubMed:9614189, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         717
FT                   /note="Phosphoserine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         720
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   MOD_RES         721
FT                   /note="Phosphoserine; by CK1 and PDPK1"
FT                   /evidence="ECO:0000269|PubMed:14761950,
FT                   ECO:0000269|PubMed:15546861, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:21327254, ECO:0000269|PubMed:9614189,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         726
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15546861,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         733
FT                   /note="Phosphoserine; by CaMK2 and TTBK1"
FT                   /evidence="ECO:0000269|PubMed:16923168"
FT   MOD_RES         739
FT                   /note="Phosphoserine; by PDPK1 and TTBK1"
FT                   /evidence="ECO:0000269|PubMed:16443603,
FT                   ECO:0000269|PubMed:16923168, ECO:0000269|PubMed:19451179,
FT                   ECO:0000269|PubMed:9614189"
FT   MOD_RES         744
FT                   /note="Phosphothreonine; by TTBK1"
FT                   /evidence="ECO:0000269|PubMed:16923168"
FT   CARBOHYD        87
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        383
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        467
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        480
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        491
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        525
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000269|PubMed:21327254"
FT   CARBOHYD        542
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        551
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        555
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000269|PubMed:21327254"
FT   CARBOHYD        576
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        597
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        598
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        664
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        670
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        686
FT                   /note="N-linked (Glc) (glycation) lysine; in PHF-tau; in
FT                   vitro"
FT                   /evidence="ECO:0000269|PubMed:9326300"
FT   CARBOHYD        717
FT                   /note="O-linked (GlcNAc) serine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21327254"
FT   DISULFID        608..639
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        44
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        571
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); in PHF-tau"
FT                   /evidence="ECO:0000269|PubMed:16443603"
FT   CROSSLNK        576
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        584
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        598
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        615
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        628
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); in PHF-tau"
FT                   /evidence="ECO:0000269|PubMed:16443603"
FT   CROSSLNK        634
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        638
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        648
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        660
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        664
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        670
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); in PHF-tau"
FT                   /evidence="ECO:0000269|PubMed:16443603"
FT   CROSSLNK        686
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        692
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   CROSSLNK        702
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P10637"
FT   VAR_SEQ         1..44
FT                   /note="MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLK -> MLRA
FT                   LQQRKR (in isoform Tau-A)"
FT                   /evidence="ECO:0000303|PubMed:2516729"
FT                   /id="VSP_003175"
FT   VAR_SEQ         45..73
FT                   /note="Missing (in isoform Tau-A, isoform Tau-D and isoform
FT                   Fetal-tau)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2498079, ECO:0000303|PubMed:2516729,
FT                   ECO:0000303|PubMed:3131773, ECO:0000303|Ref.7"
FT                   /id="VSP_003176"
FT   VAR_SEQ         74..102
FT                   /note="Missing (in isoform Tau-A, isoform Tau-B, isoform
FT                   Tau-D, isoform Tau-E and isoform Fetal-tau)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2484340, ECO:0000303|PubMed:2498079,
FT                   ECO:0000303|PubMed:2516729, ECO:0000303|PubMed:3131773,
FT                   ECO:0000303|Ref.6, ECO:0000303|Ref.7"
FT                   /id="VSP_003177"
FT   VAR_SEQ         103..104
FT                   /note="Missing (in isoform Tau-A)"
FT                   /evidence="ECO:0000303|PubMed:2516729"
FT                   /id="VSP_003178"
FT   VAR_SEQ         125..375
FT                   /note="Missing (in isoform Tau-A, isoform Tau-B, isoform
FT                   Tau-C, isoform Tau-D, isoform Tau-E, isoform Tau-F and
FT                   isoform Fetal-tau)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2484340, ECO:0000303|PubMed:2498079,
FT                   ECO:0000303|PubMed:2516729, ECO:0000303|PubMed:3131773,
FT                   ECO:0000303|Ref.6, ECO:0000303|Ref.7"
FT                   /id="VSP_003179"
FT   VAR_SEQ         395..460
FT                   /note="Missing (in isoform Tau-A, isoform Tau-B, isoform
FT                   Tau-C, isoform Tau-D, isoform Tau-E, isoform Tau-F and
FT                   isoform Fetal-tau)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2484340, ECO:0000303|PubMed:2498079,
FT                   ECO:0000303|PubMed:2516729, ECO:0000303|PubMed:3131773,
FT                   ECO:0000303|Ref.6, ECO:0000303|Ref.7"
FT                   /id="VSP_003180"
FT   VAR_SEQ         502
FT                   /note="S -> SATKQVQRRPPPAGPRSER (in isoform Tau-G)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_026780"
FT   VAR_SEQ         592..622
FT                   /note="Missing (in isoform Tau-A, isoform Tau-B, isoform
FT                   Tau-C and isoform Fetal-tau)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:2484340, ECO:0000303|PubMed:2516729,
FT                   ECO:0000303|PubMed:3131773, ECO:0000303|Ref.7"
FT                   /id="VSP_003181"
FT   VARIANT         5
FT                   /note="R -> H (in FTD1; reduces the ability of tau to
FT                   promote microtubule assembly and promotes fibril formation
FT                   in vitro; dbSNP:rs63750959)"
FT                   /evidence="ECO:0000269|PubMed:11921059"
FT                   /id="VAR_019660"
FT   VARIANT         5
FT                   /note="R -> L (in PSNP1; delays assembly initiation and
FT                   lowers the mass of microtubules formed; but the assembly
FT                   rate is increased compared to normal tau;
FT                   dbSNP:rs63750959)"
FT                   /evidence="ECO:0000269|PubMed:12325083"
FT                   /id="VAR_019661"
FT   VARIANT         17
FT                   /note="T -> M (in dbSNP:rs144611688)"
FT                   /evidence="ECO:0000269|PubMed:20020531"
FT                   /id="VAR_064622"
FT   VARIANT         30
FT                   /note="T -> A (in dbSNP:rs748728879)"
FT                   /evidence="ECO:0000269|PubMed:20020531"
FT                   /id="VAR_064623"
FT   VARIANT         285
FT                   /note="D -> N (risk factor for PSNP1; dbSNP:rs62063786)"
FT                   /evidence="ECO:0000269|PubMed:10534245,
FT                   ECO:0000269|PubMed:9629852"
FT                   /id="VAR_010340"
FT   VARIANT         289
FT                   /note="V -> A (risk factor for PSNP1; dbSNP:rs62063787)"
FT                   /evidence="ECO:0000269|PubMed:10534245,
FT                   ECO:0000269|PubMed:9629852"
FT                   /id="VAR_010341"
FT   VARIANT         370
FT                   /note="R -> W (in dbSNP:rs17651549)"
FT                   /id="VAR_056121"
FT   VARIANT         441
FT                   /note="Y -> H (in dbSNP:rs2258689)"
FT                   /evidence="ECO:0000269|PubMed:1420178,
FT                   ECO:0000269|PubMed:15365985, ECO:0000269|PubMed:9629852"
FT                   /id="VAR_010342"
FT   VARIANT         447
FT                   /note="S -> P (in dbSNP:rs10445337)"
FT                   /evidence="ECO:0000269|PubMed:9629852"
FT                   /id="VAR_010343"
FT   VARIANT         574
FT                   /note="K -> T (in PIDB; reduces the ability to promote
FT                   microtubule assembly by 70%; dbSNP:rs63750129)"
FT                   /evidence="ECO:0000269|PubMed:11089577,
FT                   ECO:0000269|PubMed:11117542"
FT                   /id="VAR_010344"
FT   VARIANT         583
FT                   /note="L -> V (in FTD1; less able to promote microtubule
FT                   assembly than wild-type tau; dbSNP:rs63750349)"
FT                   /evidence="ECO:0000269|PubMed:12509859"
FT                   /id="VAR_019662"
FT   VARIANT         589
FT                   /note="G -> V (in FTD1; dbSNP:rs63750376)"
FT                   /evidence="ECO:0000269|PubMed:9641683,
FT                   ECO:0000269|PubMed:9973279"
FT                   /id="VAR_010345"
FT   VARIANT         590
FT                   /note="G -> R (in FTD1; increased aggregation propensity
FT                   and altered binding affinity towards microtubules and
FT                   F-actin; dbSNP:rs1247408229)"
FT                   /evidence="ECO:0000269|PubMed:32961270"
FT                   /id="VAR_084361"
FT   VARIANT         596
FT                   /note="N -> K (in FTD1; with parkinsonism;
FT                   dbSNP:rs63750756)"
FT                   /evidence="ECO:0000269|PubMed:10412802,
FT                   ECO:0000269|PubMed:10489057, ECO:0000269|PubMed:10802785,
FT                   ECO:0000269|PubMed:12473774, ECO:0000269|PubMed:9789048"
FT                   /id="VAR_010346"
FT   VARIANT         597
FT                   /note="Missing (in FTD1; dbSNP:rs63750688)"
FT                   /evidence="ECO:0000269|PubMed:9973279"
FT                   /id="VAR_010347"
FT   VARIANT         613
FT                   /note="N -> H (in FTD1; reduced the ability of tau to
FT                   promote microtubule assembly without having a significant
FT                   effect on tau filament formation; effects at both the RNA
FT                   and the protein level; dbSNP:rs63750416)"
FT                   /evidence="ECO:0000269|PubMed:11585254,
FT                   ECO:0000269|PubMed:11906000"
FT                   /id="VAR_019663"
FT   VARIANT         613
FT                   /note="Missing (in PSNP1/atypical PSNP1; heterozygosity may
FT                   be a risk factor for both a PSNP1-like syndrome and
FT                   Parkinson disease; reduced the ability of tau to promote
FT                   microtubule assembly without having a significant effect on
FT                   tau filament formation; effects at both the RNA and the
FT                   protein level)"
FT                   /evidence="ECO:0000269|PubMed:11220749,
FT                   ECO:0000269|PubMed:11906000, ECO:0000269|PubMed:14991828,
FT                   ECO:0000269|PubMed:14991829"
FT                   /id="VAR_019664"
FT   VARIANT         617
FT                   /note="V -> I (in dbSNP:rs116733906)"
FT                   /evidence="ECO:0000269|PubMed:20020531"
FT                   /id="VAR_064624"
FT   VARIANT         618
FT                   /note="P -> L (in FTD1; most common mutation; reduction in
FT                   the ability to promote microtubule assembly; accelerates
FT                   aggregation of tau into filaments; dbSNP:rs63751273)"
FT                   /evidence="ECO:0000269|PubMed:10214944,
FT                   ECO:0000269|PubMed:9641683, ECO:0000269|PubMed:9736786,
FT                   ECO:0000269|PubMed:9789048, ECO:0000269|PubMed:9973279"
FT                   /id="VAR_010348"
FT   VARIANT         618
FT                   /note="P -> S (in FTD1 and CBD; reduction in the ability to
FT                   promote microtubule assembly; dbSNP:rs63751438)"
FT                   /evidence="ECO:0000269|PubMed:10374757,
FT                   ECO:0000269|PubMed:10553987, ECO:0000269|PubMed:11071507,
FT                   ECO:0000269|PubMed:16240366"
FT                   /id="VAR_010349"
FT   VARIANT         620
FT                   /note="G -> V (in PSNP1; dbSNP:rs63751391)"
FT                   /evidence="ECO:0000269|PubMed:16157753"
FT                   /id="VAR_037439"
FT   VARIANT         622
FT                   /note="S -> N (in FTD1; minimal parkinsonism; very early
FT                   age of onset; dbSNP:rs63751165)"
FT                   /evidence="ECO:0000269|PubMed:10208578"
FT                   /id="VAR_010350"
FT   VARIANT         634
FT                   /note="K -> M (in FTD1; dbSNP:rs63750092)"
FT                   /evidence="ECO:0000269|PubMed:15883319"
FT                   /id="VAR_037440"
FT   VARIANT         637
FT                   /note="S -> F (in PIDB; markedly reduced ability of tau to
FT                   promote microtubule assembly; dbSNP:rs63750635)"
FT                   /evidence="ECO:0000269|PubMed:11891833"
FT                   /id="VAR_019665"
FT   VARIANT         654
FT                   /note="V -> M (in FTD1; ultrastructural and biochemical
FT                   characteristics indistinguishable from Alzheimer disease;
FT                   accelerates aggregation of tau into filaments;
FT                   dbSNP:rs63750570)"
FT                   /evidence="ECO:0000269|PubMed:10214944,
FT                   ECO:0000269|PubMed:9629852"
FT                   /id="VAR_010351"
FT   VARIANT         659
FT                   /note="E -> V (in FTD1; dbSNP:rs63750711)"
FT                   /evidence="ECO:0000269|PubMed:11117541"
FT                   /id="VAR_019666"
FT   VARIANT         669
FT                   /note="S -> L (in fatal respiratory hypoventilation;
FT                   unusual apparent autosomal recessive inheritance; reduced
FT                   binding to microtubules as well as increased fibrillization
FT                   and aggregation; dbSNP:rs63750425)"
FT                   /evidence="ECO:0000269|PubMed:14595660"
FT                   /id="VAR_019667"
FT   VARIANT         686
FT                   /note="K -> I (in PIDB; 90% reduction in the rate of
FT                   microtubule assembly; dbSNP:rs63751264)"
FT                   /evidence="ECO:0000269|PubMed:11601501"
FT                   /id="VAR_019668"
FT   VARIANT         706
FT                   /note="G -> R (in PIDB; in vitro the mutation reduces the
FT                   ability of tau to promote microtubule assembly by 25 to
FT                   30%; dbSNP:rs63750512)"
FT                   /evidence="ECO:0000269|PubMed:10604746,
FT                   ECO:0000269|PubMed:11117542"
FT                   /id="VAR_010352"
FT   VARIANT         723
FT                   /note="R -> W (in FTD1/Alzheimer disease; accelerates
FT                   aggregation of tau into filaments; reduces tau
FT                   phosphorylation in cells compared to both the wild-type and
FT                   other mutant forms; dbSNP:rs63750424)"
FT                   /evidence="ECO:0000269|PubMed:10214944,
FT                   ECO:0000269|PubMed:11278002, ECO:0000269|PubMed:11889249,
FT                   ECO:0000269|PubMed:14517953, ECO:0000269|PubMed:26086902,
FT                   ECO:0000269|PubMed:9641683, ECO:0000269|PubMed:9973279"
FT                   /id="VAR_010353"
FT   MUTAGEN         515
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         516
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         519
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         531
FT                   /note="S->A: No decrease in microtubule-binding and
FT                   nucleation activity after in vitro phosphorylation of
FT                   mutant protein."
FT   MUTAGEN         548
FT                   /note="T->A: 50% Decrease in microtubule-binding after in
FT                   vitro phosphorylation of mutant protein."
FT   MUTAGEN         548
FT                   /note="T->E: No association with plasma membrane."
FT   MUTAGEN         552
FT                   /note="S->A: 70% decrease in microtubule-binding after in
FT                   vitro phosphorylation of mutant protein."
FT   MUTAGEN         552
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         579
FT                   /note="S->A: 8% decrease in microtubule-binding after in
FT                   vitro phosphorylation of mutant protein."
FT   MUTAGEN         713
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         721
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         726
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         730
FT                   /note="S->E: No association with plasma membrane."
FT   MUTAGEN         739
FT                   /note="S->E: No association with plasma membrane."
FT   CONFLICT        48
FT                   /note="L -> P (in Ref. 6; AAU45390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        414
FT                   /note="H -> L (in Ref. 5; AAC04277)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        557
FT                   /note="K -> M (in Ref. 12; AAS17881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        591
FT                   /note="K -> S (in Ref. 12; AAS17881)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        617
FT                   /note="V -> Q (in Ref. 17; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        622
FT                   /note="S -> K (in Ref. 17; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..9
FT                   /evidence="ECO:0007829|PDB:6N4P"
FT   HELIX           60..62
FT                   /evidence="ECO:0007829|PDB:5ZV3"
FT   TURN            63..65
FT                   /evidence="ECO:0007829|PDB:5ZV3"
FT   TURN            579..582
FT                   /evidence="ECO:0007829|PDB:6CVJ"
FT   STRAND          587..590
FT                   /evidence="ECO:0007829|PDB:5N5A"
FT   STRAND          592..610
FT                   /evidence="ECO:0007829|PDB:7P6A"
FT   STRAND          613..615
FT                   /evidence="ECO:0007829|PDB:7QK6"
FT   STRAND          618..620
FT                   /evidence="ECO:0007829|PDB:5MP5"
FT   STRAND          624..626
FT                   /evidence="ECO:0007829|PDB:8OP0"
FT   STRAND          629..631
FT                   /evidence="ECO:0007829|PDB:7QKZ"
FT   STRAND          634..643
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          645..648
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          654..660
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          662..665
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          667..671
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          673..679
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          682..684
FT                   /evidence="ECO:0007829|PDB:7P6A"
FT   STRAND          685..695
FT                   /evidence="ECO:0007829|PDB:8Q98"
FT   STRAND          698..703
FT                   /evidence="ECO:0007829|PDB:7R5H"
FT   STRAND          709..712
FT                   /evidence="ECO:0007829|PDB:7QKY"
FT   STRAND          716..720
FT                   /evidence="ECO:0007829|PDB:7SP1"
FT   STRAND          723..732
FT                   /evidence="ECO:0007829|PDB:7QKY"
FT   STRAND          734..736
FT                   /evidence="ECO:0007829|PDB:8FYU"
FT   STRAND          741..751
FT                   /evidence="ECO:0007829|PDB:7QKY"
FT   STRAND          753..755
FT                   /evidence="ECO:0007829|PDB:7QKY"
SQ   SEQUENCE   758 AA;  78928 MW;  D46C66CDBCD196E8 CRC64;
     MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG
     SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG
     HVTQEPESGK VVQEGFLREP GPPGLSHQLM SGMPGAPLLP EGPREATRQP SGTGPEDTEG
     GRHAPELLKH QLLGDLHQEG PPLKGAGGKE RPGSKEEVDE DRDVDESSPQ DSPPSKASPA
     QDGRPPQTAA REATSIPGFP AEGAIPLPVD FLSKVSTEIP ASEPDGPSVG RAKGQDAPLE
     FTFHVEITPN VQKEQAHSEE HLGRAAFPGA PGEGPEARGP SLGEDTKEAD LPEPSEKQPA
     AAPRGKPVSR VPQLKARMVS KSKDGTGSDD KKAKTSTRSS AKTLKNRPCL SPKHPTPGSS
     DPLIQPSSPA VCPEPPSSPK YVSSVTSRTG SSGAKEMKLK GADGKTKIAT PRGAAPPGQK
     GQANATRIPA KTPPAPKTPP SSGEPPKSGD RSGYSSPGSP GTPGSRSRTP SLPTPPTREP
     KKVAVVRTPP KSPSSAKSRL QTAPVPMPDL KNVKSKIGST ENLKHQPGGG KVQIINKKLD
     LSNVQSKCGS KDNIKHVPGG GSVQIVYKPV DLSKVTSKCG SLGNIHHKPG GGQVEVKSEK
     LDFKDRVQSK IGSLDNITHV PGGGNKKIET HKLTFRENAK AKTDHGAEIV YKSPVVSGDT
     SPRHLSNVSS TGSIDMVDSP QLATLADEVS ASLAKQGL
//
